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Metal ions are present in foods, water and the environment surrounding us. Some of them are 
essential to the human body, participating in numerous biological functions, whilst others are 
toxic to living life and have no physiological function. Even the metal ions which are essential 
for life, such as copper (Cu2+), iron (Fe3+) and zinc (Zn2+), are tightly regulated in the cell. Their 
excess or dysregulation is detrimental to human health. It is therefore no wonder that metal ions 
are associated with a variety of human diseases such as neurodegenerative disorders. A wealth 
of literatures links metal ions (Cu2+, Fe2+/3+, Zn2+) to Alzheimer’s disease (AD). A non-essential 
metal ion, i.e. aluminium (Al3+), is the third most abundant metal in the Earth’s crust and is 
becoming more and more bioavailable via foods and water due to environmental contamination 
and pollution. Consequently, the chronical accumulation of Al3+ is insidious to human health. 
Numerous publications have linked Al3+ to AD. However, molecular evidence underlying such 
claim is still lacking. 
AD is a devastating neurodegenerative condition that poses major challenges to human health, 
with a prevalence of around 35 million patients worldwide. One of the neuropathological 
hallmarks in AD patients is extracellular amyloid plaques which are composed of amyloid β 
peptide (Aβ) aggregates. The amyloid cascade hypothesis suggests that aggregation of the Aβ 
peptide into soluble oligomers and senile plaques is the main driver of AD. Metal ions are found 
to be present in amyloid plaques, including Cu2+, Fe2+/3+, Zn2+ and Al3+. The experimental 
evidence from the literatures thus far points to a role of metal ions in Aβ aggregation and 
pathogenesis of AD. To this end, the metal ion hypothesis for AD is proposed, which suggests 
that disruption of metal ion homeostasis promotes Aβ aggregation and onset of AD. However, 




Therefore, this thesis takes a molecular approach by NMR (nuclear magnetic resonance) 
spectroscopy to investigate the interaction of metal ions with Aβ peptide, Aβ1-28, and to analyse 
potential metal chelators for future therapeutic application, and to unravel the effect of metal 
ions on the expression of APP gene (the gene encoding amyloid precursor protein) as well as 
the antagonising effect of metal chelators against metal ions in APP gene expression.  
In this thesis, I have firstly reviewed the literatures on the metal ions, their interactions with Aβ 
peptides, their role in Aβ aggregation, and their potential involvement in AD pathogenesis. AD 
and the current hypotheses for AD pathogenesis have also been reviewed, including amyloid 
cascade hypothesis, metal ion hypothesis and oxidative stress hypothesis. I have then reviewed 
a panel of natural metal ligands that might have therapeutic potential to chelate AD related 
metals and prevent metal related oxidative stress.  
By the means of NMR, the interactions of metal ions with Aβ1-28 peptide as well as the Aβ1-28 
analogues were analysed (Chapter 3). The key binding site of Al3+ were determined. NMR data 
showed Al3+ interacts with Aβ1-28 by the NH and αH of numerous residues experiencing upfield 
shifts. Using Aβ analogues where His6, His13 and His14 were individually replaced by alanine 
residue(s) including Aβ1-28 His6A (His6 was replaced by alanine), Aβ1-28 His13A (His13 was 
replaced by alanine), Aβ1-28 His14A (His14 was replaced by alanine), and Aβ1-28 His6,13,14A 
(all His6, His13 and His14 residues were replaced by three alanine residues), I have 
demonstrated that the histidine residues (His6, His13 and His14) and N-terminal Asp1 were 
involved in the Al3+ coordination. By comparing Al3+ to Zn2+, a relatively well-studied metal 
ion for its interaction with Aβ, this study found that Al3+ has a similar affinity to Aβ1-28. 
Additionally, the change of chemical shift index (CSI) values caused by Al3+ coordination 




The above findings are reported for the first time, because there are no available details for the 
molecular interaction between Al3+ and Aβ. The results provide significant evidence for the 
potential role of Al3+ in Aβ aggregation, hence in AD aetiology.  
The ability of metal ions interacting with Aβ in vitro means such interaction is potentially 
existent in vivo. Therefore, reducing the metal availability by metal chelation would minimise 
metal ions’ interaction with Aβ. Therefore, the metal coordination of a panel of chelating 
ligands was characterised in Chapter 4. These ligands are histidine, glutathione (GSH), maltol, 
citric acid and malic acid. They are naturally occurring, easily metabolised and nontoxic to 
humans.  
The panel of ligands were characterised by NMR and molecular mechanics to explore their 
ability in metal coordination. The findings demonstrated that they can coordinate Al3+, Cu2+ 
and Zn2+. GSH and histidine in particular exhibited much higher affinity to Al3+, Zn2+ and Cu2+. 
Considering the previously proven antioxidant property for both GSH and histidine, their ability 
to chelate metal ions could be of significance to treatment of metal-related disorders such as 
AD.  
Following the NMR and molecular mechanics analysis, MTT (3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide) toxicity assays (Chapter 5) were used to determine the 
potential of the metal ligands in cellular context. Citric acid, was effective at reducing the metal 
toxicity of 1 mM Al3+, however significantly decreased the cell viability in cells exposed to 
Zn2+. The ligands, GSH and histidine were overall more effective at ameliorating the metal 
toxicity of Al3+, Zn2+ and Cu2+ as well as nonrelated AD metal ion As3+ and Cr6+. Moving on 
to the effect of metal ions on APP gene expression, the findings demonstrated that the relative 




Al3+ and Zn2+, suggesting that these two metal ions are likely to induce higher level of amyloid 
precursor protein and consequently more Aβ. The upregulation of APP gene expression by 
metal ions is a novel finding for human neuronal cells, although similar result was found in 
animal models. It is significant, since such modulation of APP gene expression by metal ions 
could happen in vivo, therefore supporting the current hypothesis that metal ions are involved 
in AD pathogenesis.  
Moreover, the findings demonstrate that chelating ligands such as histidine and GSH reduced 
the expression of APP gene. Whilst the mechanism of histidine and GSH in reducing APP gene 
expression is not clear, the finding is of significance in that metal chelation could be at least a 
strategy to be considered for AD treatment. Future studies on this front is definitely warranted. 
In conclusion, the findings of this study provide significant evidence for the interaction of metal 
ions with Aβ. The molecular details of Al3+ and Zn2+ with Aβ and its role in upregulating APP 
gene expression are novel. Therefore, the findings support the unification of the amyloid 
cascade and metal ion hypotheses. That the metal chelating ligands histidine and GSH can 
antagonise the effect of metal ions on APP gene upregulation provides a significant avenue for 
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1  LITERATURE REVIEW 
 General introduction 
Metal ions such as aluminium (Al3+), zinc (Zn2+), ferrous (Fe2+) and cupric (Cu2+) are implicated 
in the formation of amyloid β (Aβ) peptide aggregates. Aβ aggregation is a hallmark of 
Alzheimer’s disease (AD) (Adlard and Bush, 2006; Nair et al., 2010). The outset this thesis 
aims to investigate the interaction of metal ions with Aβ, therefore the findings have bearing on 
the understanding of AD, a progressive neurodegenerative condition with yet to be defined 
mechanism (Arispe et al., 2010; Ballard et al., 2011). Various factors such as genetic mutations, 
amyloid precursor protein (APP) processing, Aβ and metal ions have been identified to play a 
role in AD (Barber, 2012; Lanoiselée et al., 2017). Majority of AD cases are sporadic, not 
genetically related, with no defined causal mechanisms (Huat et al., 2019). One school of 
thoughts proposed by a body of experimental findings is that the Aβ peptide serves as a ligand 
for metal ions and their interactions can eventuate into Aβ aggregation accompanied with 
oxidative stress in brain (Pearson and Peers, 2006; Bush and Tanzi, 2008; Duce et al., 2011). 
As metals are natural constituents of the earth’s crust, they are inextricably relevant to living 
organisms, whether they are biologically essential or non-essential. Human exposure to metals 
constantly increases because of their exponential applications in a variety of industries. 
Consequently, this study will firstly characterise the interaction of Aβ1-28 with metal ions, I will 
then investigate variety of organic chemical ligands for their interaction with a range of metal 
ions. The aims are to develop suitable ligands for therapeutic application as metal ion chelators, 




The interaction of metal ions with Aβ will be analysed in this project, using Aβ1-28, by nuclear 
magnetic resonance (NMR) spectroscopy, primarily focusing on the highly neurotoxic Al3+, as 
neither its coordination to Aβ peptide nor its implication in AD have yet been established 
(Tomljenovic, 2011; Walton, 2012). Characterisation of the interactions of metal ion and Aβ 
will be conducted by 1H (proton), NOESY (Nuclear Overhauser Effect SpectroscopY) and 
TOCSY (TOtal Correlated SpectroscopY) NMR. Previous studies have demonstrated that the 
N-terminal Asp1 and all the three histidine (His6, His13 and His14) residues of Aβ coordinate 
with metal ions (Danielsson et al., 2007). Aβ peptide analogues were synthesised chemically in 
this study by substitution of individual histidine residues with alanine which has a short and 
uncharged side chain in order to dissect the role of histidine residues of Aβ in metal ion 
coordination. Furthermore, this study will likely reveal other potential coordinating sites such 
as the arginine residue (Arg5), serine (Ser8), glutamic acid (Glu11) and tyrosine (Tyr10). 
The characterisation of a panel of ligands, including histidine, glutathione (GSH), 3-hydroxy-
2-methyl-4H-pyran-4-one (maltol), citric acid and malic acid for their interactions with 
biometals (Zn2+ and Cu2+) and non-biological metal ion (Al3+) has been conducted to uncover 
potential natural metal chelators. The interaction of metal ions and the ligands was analysed 
using 1H NMR titration experiments, to demonstrate where the metals coordinate to the 
complexes. The coordination strength and stability of the complexes of the metals to ligands 
was determined by molecular mechanics (MM2 calculations and HOMO values). Mammalian 
neuronal cell culture system was also employed for measuring the effect of ligand on metal 
toxicity in the cells by the colorimetric cell-proliferation assay called MTT assay which uses 
the tetrazolium salt MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) 
(Mosmann, 1983), in order to determine the ability of the ligands in lowering metal toxicity 




demonstrated whether the ligands can chelate highly toxic metals although they are not related 
to AD, and the findings could lead to application of potential metal chelators for alleviating the 
toxic metal related health problems.  
On the basis of the published evidence (Lin et al., 2008), albeit very limited, it is hypothesised 
that metal ions could also affect the expression of APP gene. Quantitative RT-PCR (Reverse 
Transcription Polymerase Chain Reaction) was used to test whether the expression of APP gene 
in human SH-SY5Y neuronal cells is affected by metal ions such as Al3+ and the extensively 
studied Zn2+. To explore the antagonistic effect the ligands have on metal ions, qRT-PCR was 
used to measure APP gene expression level in the presence of the ligands and Al3+. 
My thesis is of significance on a number of fronts. The molecular details gained from 
characterising the interaction of metal ions with Aβ should provide support to the notion that 
metals ions interact with Aβ. The effect of metals on APP gene expression has been scarcely 
studied until the present, findings on this front should aid our understanding of AD in terms of 
the potential role for metal ions in AD pathogenesis. By screening a spectrum of potential 
ligands for metal chelation, findings should benefit the development of therapeutic drugs for 
metal-related health problems such as AD and acute metal poisoning. 
To summarise simply, the aims of this study are firstly to characterise the interactions between 
metal ions and amyloid β peptide (Aβ); then to analyse the interactions between metal ions and 
metal-chelating ligands; finally, to uncover the effect of metal ions on the expression of APP 




 Metal ions 
Metals ions are constituents of the Earth’s crust. Around 95 of the 118 elements in the periodic 
table are metals. Metal ions are central to protein structure and function. Many metal-binding 
proteins are enzymes which are present in the early forms of life, prokaryotes, and continued in 
eukaryotes (Wiiliams, 2012). Roughly 40% of all proteins crystallized to date have a metal 
bound within the structure and thought to be relevant to function (Waldron et al., 2009). The 
most abundant metal ion in living organisms is iron, followed by zinc. Metal ions and life have 
been evolving together (Hong Enriquez and Do, 2012). The complexity of organisms, 
especially in three steps, prokaryotes, single-cell and then multi-cell eukaryotes, coincides with 
oxygen-related environmental changes in the evolution of life. For example, the rise of oxygen 
caused a rise of zinc in the sea as estimated from the analysis of sediments (Hong Enriquez and 
Do, 2012). During the long evolution process, organisms learned to use or to avoid certain metal 
ions. Hence, there are essential or non-essential metal ions to living organisms. 
 
 Metal ions and biology 
The essential metal ions can be further divided into two camps, including one group which is 
needed in larger quantity by the organisms (e.g. Ca2+, Mg2+), and the other group which are in 
much lower abundance such as the trace metal ions such as Fe2+/3+, Cu+/2+ and Zn2+. A tenet of 
the cell biology of metals is that some metals tend to bind organic molecules more avidly than 
others. The natural order of stability for divalent metals, often called the Irving–Williams series 
(Irving and Williams, 1948), sets out a resulting trend with copper and zinc forming the tightest 




the weakest complexes, calcium and magnesium. Zinc is a quintessential metal in metal 
biology. Going back chronologically, zinc was first found essential to living organism in 1869, 
by Jules Raulin, a student of Louis Pasteur (Raulin, 1869). It is involved in enzymatic catalysis 
as a cofactor, structural component in proteins and signal transduction as a second messenger 
(Hershfinkel et al., 2001; Laity et al., 2001; Maret, 2001; Taylor et al., 2012). The first zinc 
binding enzyme discovered is carbonic anhydrase (Keilin and Mann, 1940). It is estimated that, 
in human proteome, there are at least 3000 zinc-binding proteins (Maret, 2012). Many of these 
proteins are transcription factors for DNA binding and gene regulation (Ebert and Altman, 
2008). For non-essential metals, their presence in living organisms is deleterious. For example, 
aluminium (Al3+) has no biological role in organisms. However, Al3+ ions are taken up by 
humans via drinking water and diet. With climate change and environmental pollution, the 
acidity of soil is increasing, which leads to the increased solubility of aluminium minerals and 
increased abundance of Al3+ ion in drinking water, plants and foods, and in turn more Al3+ ions 
are accumulated in people. Therefore, aluminium is associated with AD (Huat et al., 2019), 
although more evidence is required for such a link.  
The excess of essential metal ions such as Fe2+/3+, Cu1+/2+ and Zn2+ is harmful to humans. Their 
optimal physiological concentration range between deficiency and toxicity is relatively small 
and needs to be tightly controlled. The cellular process to maintain the metal level at optimum 
is termed as homeostasis. Metal dyshomeostasis results from the disruption of metal 
homeostasis, which can lead to health disorders. For non-essential metals such as cadmium and 
hexavalent chromium, tiny amounts of them could promote severe toxicity to the cell 




The omnipresence of metals in our quotidian lives presents innumerable hazards and health 
risks, albeit many of them are essential to human health. It is well known that metals are 
associated with many chronic health conditions as well as acute toxicity. World Health 
Organization (WHO) (2010) approximates metals are accountable for a significant mortality 
and morbidity, with 25% of total burden of disease linked to metal exposure. Metal ions have 
been found to interact with cell components such as DNA and nuclear proteins, causing DNA 
damage and conformational changes that may lead to cell cycle modulation, carcinogenesis or 
apoptosis (Wang and Shi, 2001; Beyersmann and Hartwig, 2008). Their toxicity depends on 
several factors including the dose, route of exposure, and chemical species, as well as the age, 
gender, genetics, and nutritional status of exposed individuals (Touchette et al., 2010). 
Essential metals are inextricably involved in numerous essential biological processes and 
enzymatic reactions of the cell. For examples, iron (Fe2+ or Fe3+) is a crucial part of 
haemoglobin for oxygen or carbon dioxide transport (Gupta, 2014). Many enzymes require 
copper (Cu+ or Cu2+) and zinc (Zn2+) to serve as cofactors or prosthetic groups (Tchounwou et 
al., 2012). Their import into the cell, intracellular trafficking, and export out of the cell must be 
tightly regulated at the cellular level, in order to maintain homeostasis. Metal dyshomeostasis 
can result in serious diseases such as cancers and neurodegenerative disorders like AD (Akatsu 






 Alzheimer’s disease 
Alzheimer’s disease (AD) was firstly reported on November 3, 1906 by a clinical psychiatrist 
and neuroanatomist - Alois Alzheimer, as a progressive neurodegenerative condition (Hippius 
and Neundörfer, 2003). AD is the most common form of dementia, by 2020 it is estimated to 
affect 50 million people worldwide, of which more than 400 000 reside in Australia (Macaulay 
and O'Meara, 2011; Hebert et al., 2013). Such a high global prevalence leads to serious 
socioeconomic burden and poses major challenges for human health in the 21st century. The 
clinical symptoms of AD are progressive cognitive deterioration and decline in memory. 
Initially the decline in memory occurs via the loss of episodic memory, which is a declarative 
memory subcategory, leading to a reduction in the ability to recollect recent events (Chopra et 
al., 2011). The molecular mechanism that causes the cognitive deterioration and decline in 
memory seen in AD remains an open question, albeit a considerable quantity of studies has 
been carried out until the present.  
The disease is characterised by neuronal and synaptic loss resulting in gliosis and tissue atrophy. 
The histopathological hallmarks of AD, known as senile plaques and neurofibrillary tangles 
(Lau et al., 2002), are primarily found in the temporal and frontal cortices (Serrano-Pozo et al., 
2011). The extracellular senile plaques were described as a “peculiar substance” by Alzheimer 
(Hippius and Neundörfer, 2003). In 1984, Glenner and Wong found senile plaques consisted of 
fibrils, which are made up of an aggregated Aβ peptide (Glenner and Wong, 1984). The 
intraneuronal neurofibrillary tangles are composed of paired helical filaments of 
hyperphosphorylated Tau protein (Zatta et al., 2009). The intraneuronal aggregates of 
hyperphosphorylated and misfolded Tau become extraneuronal (“ghost” tangles) when tangle-




spatiotemporal progression that correlates with the severity of the cognitive decline (Serrano-
Pozo et al., 2011). 
There are two forms of AD, the familial and sporadic AD. The familial AD is also called early-
onset AD, accounts for only 5% of cases (Perrone et al., 2012). It occurs from the gene 
mutations in the presenilins (PS1& PS2), the APP genes of chromosome 1, 14 and 21 
respectively and apolipoprotein isoform gene (ApoE4) (Tanzi et al., 1996; Mattson, 2004; 
Lanoiselée et al., 2017). However, the majority of cases are sporadic AD which is not due to 
genetic mutations. Sporadic AD has consistent pathological and clinical characteristics similar 
to familial AD but has a later age of onset (Kern and Behl, 2009; Pimplikar et al., 2010). 
Although the senile plaques and neurofibrillary tangles are characteristic lesions for both forms 
of AD, the molecular mechanism that initiates the pathogenesis in sporadic AD is not fully 
understood. Recent advances of research activities demonstrated that the Aβ is associated to the 
AD pathology and considered a critical factor in the pathogenesis of sporadic AD (Hardy and 
Selkoe, 2002). However, that the very existence of Aβ aggregation in the disease is a cause or 
a by-product of AD still remains debatable (Hardy, 2006; Lee et al., 2007; Korczyn et al., 2008). 
Experimental findings supporting the role of Aβ in AD pathogenesis are numerous, only a few 
examples are described in the following. Transgenic mice containing the APP gene mutation of 
Lys670 → Asn, Met671 → Leu, lead to increased production of human Aβ resulted in behavioural 
and memory deficits characteristic of AD (Hsiao et al., 1996). The conformational transition of 
the secondary structure of Aβ from random coil to β sheet increased the neurotoxicity of the 
peptide (Ueda et al., 1994). Aggregation of Aβ into amyloidogenic fibrils was found to produce 
neurotoxic compact plaques, in primary rat hippocampal cultures (Lorenzo and Yankner, 1994). 
Although these findings illustrate that the aggregation of Aβ is likely a crucial event in the 




elucidated. This study will seek to reveal some details on how metal ions interact with Aβ, 
which could play a role in Aβ aggregation and consequently AD. 
 
 Amyloid precursor protein (APP)  
The Aβ peptide is generated after two consecutive cleavage events by β- and γ-secretases of 
APP encoded by APP gene, a type-1 transmembrane protein with a single transmembrane span 
and an extracellular N-terminus. APP can also be cleaved by α-secretase within the Aβ domain 
to release soluble APP derivative and preclude Aβ generation (Zhang et al., 2011). As 
previously mentioned, genetic mutations in APP, as well as in presenilins (PS1 and PS2), are 
the cause for familial AD. Also mentioned is that Aβ could play a role in the pathogenesis of 
sporadic AD. Therefore, it is significant to recognise that APP is a critical protein for AD. 
APP is expressed in various tissues, especially in the central nervous system (CNS). It is 
synthesised in the endoplasmic reticulum and then transported to the Golgi apparatus, where it 
completes maturation and is finally transported to the plasma membrane. Although its 
physiological function is still unclear, APP could play an important role in brain development, 
memory and synaptic plasticity (Breen et al., 1991). It is suggested that APP is involved in 
neurite outgrowth and synaptogenesis, neuronal protein trafficking along the axon, 
transmembrane signal transduction, cell adhesion and calcium metabolism (Zheng and Koo, 





Figure 1.1 Schematic of APP proteolytic cleavage. In the non-amyloidogenic pathway, APP 
is cleaved by α-secretase and then γ-secretase or β-secretase to form truncated Aβ17–40/42 or Aβ1–
16 peptides respectively. In the amyloidogenic pathway, APP undergoes consecutive cleavage 
by the β- and γ-secretases, producing Aβ40/42 peptide. 
Physiological APP undergoes non-amyloidogenic cleavage, predominantly in post-Golgi 
secretory and endocytic compartments, by α-secretase and γ-secretase, producing soluble APP. 
The amyloidogenic pathway occurs at the plasma membrane where the APP cleavage is 
sequentially conducted by β-secretase and γ-secretase. This pathway releases Aβ. As shown in 
Figure 1.1, both cleavage pathways for APP lead to the formation of carboxyterminal fragments 
(C83) and amino-terminal fragments secreted APP (sAPPα and sAPPβ). Then followed by the 
formation of amino-terminal APP intracellular domain (AICD), this fragment is involved in 
nuclear signalling (Chow et al., 2010). Both non-amyloidogenic and amyloidogenic pathway 
occur under normal conditions in all cells (Haass et al., 1992). During neuronal activity, Aβ is 
formed intracellularly in vesicles such as endosomes, then released into the extracellular space 




multifactorial and involves the disruption of multiple mechanisms. However, the soluble form 
of Aβ is found in healthy brain but the aggregated form is in the brain of AD patients (Glenner 
and Wong, 1984). Hence numerous hypotheses have been postulated to elucidate the 
mechanism responsible for the development of senile plaques. In this thesis, the interaction of 
metal ions with Aβ peptide is investigated, and the effect of metal ions on APP gene expression 
is also investigated.  
Thus far there is scant evidence on the effect of metal ions on APP gene expression. It was 
demonstrated that cupric and manganese (Mn2+) ions potently increased the expression of APP 
gene in a time- and concentration-dependent manner (Lin et al., 2008; Kim et al., 2018). As 
metal ions such as Al3+ are implicated in AD (Exley, 2014; Exley and Vickers, 2014), their 
effect on Aβ aggregation as well as APP gene expression needs to be studied. Therefore, 





 Amyloid β (Aβ) peptide 
Aβ was firstly characterised in 1984 by Glenner and Wong (1984). It is a soluble cellular 
metabolite found in cerebrospinal fluid (CSF) and plasma (Yang et al., 2000). As described 
previously, Aβ is produced by a variety of cells, from the sequential proteolytic processing of 
the APP by secretases β and γ (Glenner, 1985; Lahiri and Maloney, 2010). 
Aβ encompasses a group of peptides ranging in size from 12 to 42 amino acid residues. The 
primary amino acid sequence of the 42-residue Aβ isoform Aβ42 is shown in Figure 1.2. The 
C-terminal amino acid sequence of Aβ is mainly composed of hydrophobic residues, which 
performs an important part in its insolubility and in the initial steps of aggregation. The N-
terminal region of Aβ is amphipathic and participates in the binding of Aβ to apoE (Strittmatter 
et al., 1993), cholesterol (Yao and Papadopoulos, 2002), glycosaminoglycans (Narindrasorasak 















Aβ is thought to be an intrinsically unstructured peptide. The secondary and tertiary structure 
is extensively influenced by environmental milieu, for example, in membrane-like media, the 
truncated 28 residue long Aβ peptide (Aβ1-28) folds into a predominately α-helical structure with 
a bend centred at residue Val12 (Talafous et al., 1994). Without a defined tertiary structure, 
studies of its physiological functions are difficult. Emerging data suggests Aβ plays important 
physiological roles, such as controlling synaptic plasticity (Kamenetz et al., 2003) involved in 
regulatory neurogenesis, metal ion homeostasis or sequestration, oxidative stress protection, 
calcium regulation (Cardenas-Aguayo Mdel et al., 2014), immune response and signaling 
pathways (Ramanathan et al., 2015). Brain disruptions, for example a stroke and trauma, results 
in an irregular up regulation of APP and accumulation of Aβ (Pierce et al., 1996; van Groen et 
al., 2005). While the primary function of Aβ still remains to be established, in the brain of AD 
patient it is in the aggregated form, and in healthy brain tissue it is in the soluble form.  
Although decades have passed since Aβ was characterised and associated with AD, how it 
forms aggregates in the brains of AD patients is still unknown. Multiple factors such as pH, 
temperature, peptide concentration, and ionic strength have been implicated in the formation of 
Aβ aggregates (Meisl et al., 2016). However, the extracellular increase of Aβ concentration in 
the brain has been found to result in Aβ aggregation, forming β-sheet rich structures which are 
characteristic of AD (Ding and Keller, 2003). Aggregation begins with the formation of 
oligomers species, these are then re-arranged into protofibrils and fibrils which are found in 
senile plaques. As the oligomer species in AD patient brains can permeabilize cellular 
membranes, which consequently initiate a series of events resulting in cell dysfunction and 





To ensure this study is relevant to the biological reality, it will be conducted at the biological 
pH of 7.4. In terms of studying the peptides by 1H NMR analysis, previous studies have 
illustrated the tendency for Aβ40 to undergo rapid conformational changes, causing large up 
field shifts. This property would cause the characterisations of the resulting metal-ligand 
complex difficult, thus the use of larger peptides would not be feasible in this project. Also, the 
longer peptides, such as Aβ42, can rapidly aggregate and suddenly form fibrils. Therefore, when 
compared to the larger counterparts, the truncated 28 residues long Aβ peptide (Aβ1-28) is 
practically more manageable, in regard to its propensity to precipitate or aggregate out of a 
solution. Shorter Aβ peptides cannot be used as under biological conditions pH of 7.4, it will 
not undergo aggregation (Mekmouche et al., 2005), thus rendering secondary structural studies 
less relevant to the disease development. Furthermore, Aβ1-28 contains three histidine residues 
which are possibly involved in metal coordination. Hence this study will use the Aβ1-28, with 
the sequence of DAEFRHDSGYEVHHQKLVFFAEDVGSNK. Since the precise mechanism 
of Aβ aggregation is yet to be identified, it is expected that the outcome of this study can 
enhance our understanding of Aβ aggregation in terms of the role of metal ions in the process. 
 
 Oxidative stress and Alzheimer’s disease 
Another feature of AD is its association with oxidative stress. Oxidative stress occurs with the 
increased production of reactive oxygen species (ROS), caused by the inadequate detoxification 
of cellular antioxidant defence system. ROS is a collective term for oxygen radicals (superoxide 
and hydroxyl) and non-radical derivatives (hydrogen peroxide), they bear unpaired electrons 
(Kim et al., 2015). ROS are very unstable and readily cause damages in macromolecules such 




The brain is susceptible to oxidative stress as a result of relatively low concentrations of 
antioxidants, higher levels of polyunsaturated fatty acids and the elevated oxygen requirements 
(Evans, 1993; Huang et al., 2016). In particular, the mitochondria is a major source of oxidative 
stress, as it requires high levels of oxygen for the energy production (Bhat et al., 2015). A 
characteristic pathological feature of AD is oxidative stress and mitochondrial dysfunction. In 
AD patients, in the neocortex exhibits metabolic markers of oxidative stress include free radical 
induced damage of brain proteins, lipids and DNA. Increased concentration of redox active 
metals ions, Cu2+ and Fe2+ result in the production of ROS via the involvement in Fenton 
reactions and Haber-Weiss reaction. These reactions are shown below in Equations 1.1 to 1.3- 
Fenton reactions:             Mn+ + H2O2  →  MI
(n+1)+ + HO• +  OH−                               (1.1) 
M(n+1)+ + H2O2  →  MI
n+ + HOO• + H+                                 (1.2) 
 
Haber-Weiss reaction:          O2
•− + H2O2  →  O2 + HO
• + OH−                                           (1.3) 
The biochemical relationships amongst Aβ, metal ions, plaques, oxidative stress and AD is 
multifaceted and intriguing. In vitro evidence suggests Aβ plays a role in oxidative stress in AD 
brain, such as synthesised Aβ can cause lipid peroxidation of synaptosomes (Butterfield et al., 
1994). The coordination of Cu2+ and Fe3+ to Aβ has been found to catalyse the production of 
ROS, in particular the highly reactive hydroxyl radical (Nakamura et al., 2007). Aβ is also able 
to reduce Cu2+ to Cu+ and Fe3+ to Fe2+, simultaneously generating ROS, hydrogen peroxide and 
hydroxyl radical (Huang et al., 1999). The mechanistic reaction of this is detailed by Huang et 






 2Aβ + M(n+1)+ →  (Aβ − Aβ•)+ + Mn+                              (1.4) 
Mn+  + O2  →  MI
(n+1)+ + O2
−                                       (1.5) 
 O2
−  + O2
− + 2H+ →  H2O2 + O2
•                                   (1.6) 
This subsequently demonstrates a relationship between Aβ, metal ion and oxidative stress. On 
one hand, Aβ production and metal ions can play an important role in the oxidative process and 
subsequent mitochondrial dysfunction seen in AD (Sayre et al., 2005; Murakami et al., 2012; 
Trist et al., 2018). On the other hand, metal dyshomeostasis and oxidative stress are major 
factors that trigger the production and oligomerization of Aβ in AD (Butterfield, 2002; Drago 
et al., 2008; Tabner et al., 2011; Murakami et al., 2012). Therefore, the interactions between 
oxidative stress, metal ions and Aβ may be the multifaceted culprits which trigger and 
accelerate AD pathogenesis.  
 
 AD pathogenesis hypotheses 
In the past decades, many different hypotheses for AD pathogenesis have been proposed. Some, 
such as the cholinergic hypothesis of AD state cognitive impairment comes from dysfunction 
of acetylcholine (Francis et al., 1999). However, trials to inhibit this pathway with symptom-
treating receptor antagonists, had limited efficiency (Weinstock, 1995). Hence the quest for 
more causative pathogenic targets continues until the present. Stemming from the different 
features of the disease, the three main hypotheses have emerged, i.e., amyloid cascade 
hypothesis, metal ion hypothesis and oxidative stress hypothesis. A major theme of my study 
is the interaction between Aβ and metal ions as well as the oxidative process surrounding this 




 Amyloid cascade hypothesis 
Although multiple risk factors have been associated with the sporadic AD, it is not clear what 
factors can cause the disease. However, one thing is almost certain, that is, Aβ is linked to AD, 
albeit whether it is the cause or effect is still debatable. The ‘amyloid cascade hypothesis’ is the 
most influential model for the pathology of AD proposed over the last 25 years (Karran and De 
Strooper, 2016). It suggests the deposits of Aβ aggregates in the brain is imperative step in the 
development of AD (Hardy and Higgins, 1992). The abnormal processing of APP, as well as 
its aberrant metabolism, causes excessive Aβ in the brain, therefore, resulting in Aβ 
aggregation, neurodegeneration and neuronal call death accompanied with AD (Budimir, 
2011). 
This hypothesis is supported firstly by the discovery of the APP gene which exists on 
chromosome 21. APP gene is mutated in both familial AD and Down syndrome (Barber, 2012). 
Secondly, observations of individuals with Down syndrome are affected by neuropathological 
features indistinguishable from AD patients (Olson and Shaw, 1969; Glenner and Wong, 1984). 
Studies showed that in Down syndrome the temporal sequence of events initiated with the 
formation of plaques, followed by the development of neurofibrillary tangles and the 
subsequent neuronal cell damage also seen in AD (Rumble et al., 1989). 
As the amyloid cascade hypothesis suggests that Aβ deposition in the brain is the cause of AD 
(Hardy and Higgins, 1992), thus implying that if Aβ deposition is eliminated, AD would be 
cured or ameliorated in human subjects. However, the data accumulated in the years after the 
hypothesis proposed, even Hardy himself (Hardy, 2009) asked the provocative question, “Has 
the amyloid cascade hypothesis for Alzheimer's disease been proved?”. Clinical trials with Aβ-




peptide (AN-1792) and adjuvant QS-21 was the first active immunotherapy for AD (Robinson 
et al., 2004; Lee et al., 2005). The therapy was based on AN-1792 provoking the immune 
response in order to eliminate amyloid deposits in brain (Nicoll et al., 2003). Preclinical 
evidence demonstrated the therapy prevented Aβ deposition. However, Phase IIA trials were 
suspended in early 2002 when 6% of patients, who received the vaccine, developed 
meningoencephalitis (Robinson et al., 2004; Gilman et al., 2005). Despite the trials being 
abandoned, studies found Aβ immunotherapy can be beneficial in AD, as post mortem analysis 
demonstrated the clearance of senile plaques in the immunised group (Holmes et al., 2008). The 
amyloid cascade hypothesis has continued to gain support in the past two decades, with genetic 
studies and many current treatment strategies intending to reduce Aβ production or increase Aβ 
metabolic rate (Barage and Sonawane, 2015).  
 Metal ion hypothesis 
With what specifically initiates the excessive Aβ and the variation in its metabolism still 
unknown, and the incomplete success for therapeutic anti-amyloid drugs, numerous studies 
point to the other factor, i.e. metal ions. This is triggered by the fact that metal ions were found 
in amyloid plaques and that Aβ accumulation and aggregation can be markedly affected by 
metal ions in the brain (Bolognin et al., 2011; Kim et al., 2018). The ‘metal ion hypothesis’, 
also known as the ‘neurotoxic trace element hypothesis’, suggests that the aggregation of Aβ 
and its neurotoxicity is mediated by metallochemical reactions, as well as impaired metal 
homeostasis (Bush and Tanzi, 2008). The metal ion hypothesis indicates that the interaction of 
Aβ with metal ions is the causative factor of neuronal cell loss and AD (Blessed et al., 1968; 
Mann and Esiri, 1989; Selkoe, 1991; Kim et al., 2018). In support of the metal hypothesis, it 




copper (Cu2+), zinc (Zn2+) and aluminium (Al3+) in cerebral Aβ deposits such as senile plaques 
(Cherny et al., 2001; Bush et al., 2003; Miller et al., 2006). An important breakthrough for the 
metal ion hypothesis, was numerous observations that Al3+, Zn2+, Fe2+ and Cu2+ are essential 
for formation and structural integrity of Aβ aggregates, oligomers, and fibrils (Atwood et al., 
1998; Lovell et al., 1998; Dong et al., 2003; House et al., 2004; Huang et al., 2004; Miller et 
al., 2006; Talmard et al., 2009). Metal ions can also bind to the location of the γ-secretase 
cleavage, which subsequently limits the cleaving by β-secretase (Bush et al., 1993). This results 
in the increased production of Aβ. 
 Oxidative stress hypothesis 
The third hypothesis of AD pathogenesis asserts that age, environmental or genetically 
enhanced oxidative stress results in the gene defects and declining mitochondrial function and 
triggers the pathogenesis of AD (Markesbery, 1997; Bhat et al., 2015; Cheignon et al., 2018). 
The oxidative stress leads to neurological disorders, by initiating apoptosis in neurons 
(Nakamura et al., 2007; Dumont and Beal, 2011). The neurological apoptosis occurs by 
triggering a range of pathways from lesions, misfolded proteins, excitotoxicity or 
Ca2+ dyshomeostasis (Beal, 1995). Numerous post mortem human studies support that 
oxidative stress is a constant feature of the AD brain pathology, with the increased oxidative 
stress biomarkers and ROS-oxidized proteins detected in the frontal and parietal lobes and in 
the hippocampus of AD (Subbarao et al., 1990; Hensley et al., 1995; Smith et al., 1997; 
Markesbery and Carney, 1999; Lauderback et al., 2001; Butterfield et al., 2006). Mice models 
demonstrate oxidative stress features of lipid and protein oxidation is present in the early 




indicated in section 1.7, Aβ aggregates have the potential to form ROS. Hence the 
neurodegeneration around the amyloid plaques are also associated to oxidative stress. 
 Alzheimer’s disease multifactorial nature  
The amyloid cascade hypothesis, metal ion hypothesis and oxidative stress hypothesis reveal 
the multifactorial nature of AD, with several pathological factors such as oxidation, 
inflammatory response, disruption of metal ion homeostasis considered as both the triggers and 
subsequent events of Aβ aggregation (Mantyh et al., 1993; Hou et al., 2004; Huang et al., 2004; 
Kurganov et al., 2004; Boyd‐Kimball et al., 2005; Hung et al., 2008; Bolognin et al., 2011; 
Meisl et al., 2016). While the etiological mechanism of AD remains unclear, evidence supports 
the notion that metals are critically involved as factors or cofactors in AD etiopathogenesis. 
Many features of the three hypotheses are inextricably linked via metal ions, as shown in Figure 
1.3. Metal ions are related to both Aβ aggregates and oxidative stress, indicating a consequential 





Figure 1.3 Schematic description of the hypotheses for Alzheimer’s disease. Amyloid β (Aβ) 
monomers produced via the cleavage of APP (amyloid precursor protein) by β- and γ- secretase. 
In the amyloid cascade hypothesis Aβ monomers aggregate, resulting in the formation of amyloid 
plaques (image sourced from Tschanz, 2011)which in turns cause AD. The production of ROS 
plays a major role in the oxidative stress hypothesis. ROS are believed to be either the cause or 
a by-product of Aβ aggregation and amyloid plaques. ROS can also be formed by Fenton-like 
reactions through the binding of Aβ monomers to Cu+/2+ or Fe2+/3+, leading to Aβ aggregation 
and amyloid plaques. The metal ion hypothesis highlights metal dyshomeostasis which leads to 
Aβ aggregation and AD. These three hypotheses are connected, as metal ions can be involved in 




 Metal ions associated with Alzheimer’s disease 
The dyshomeostasis of the brain’s metal ions promotes Aβ aggregation. In the case of copper 
and iron, they can generate reactive oxygen species, which may involve in AD development 
(Bush and Tanzi, 2008; Drew, 2017). Donnelly et al (2007) referred to Aβ as metal sinks due to 
the high concentration of metals in Aβ plaque. Metals Al3+, Zn2+, Cu+/Cu2+ and Fe2+/Fe3+ have 
been found in amyloid plaque of AD patients at concentration of 0.5-1 mmol L-1 (Faller and 
Hureau, 2009). Along with the global warming and elevated environmental pollution, our 
exposure to metal ions increases and this in turn adversely affects human health. The role of 
metal ions (targeted in this study i.e. copper, zinc, aluminium, arsenic and chromium) in Aβ 
coordination and aggregation has been investigated in the past years, the findings are reviewed 
below. 
 Copper 
Copper has a major role in brain metabolism, it is essential for Cu/Zn superoxide dismutase 
(SOD1) for antioxidant defence, electron transport, mitochondrial respiratory chain, dopamine 
β-hydroxylase, biosynthesis, and ceruloplasmin for iron homeostasis (Waggoner et al., 1999; 
Donnelly et al., 2007). Cu2+ homeostasis is particularly important, as concentrations of free Cu2+ 
exceeding 10−18 M can cause oxidative damage (Rae et al., 1999). Numerous studies have 
indicated Cu2+ homeostasis is severely impaired in AD (Brown and Kozlowski, 2004; Gaggelli 
et al., 2006). Elevated concentrations of Cu2+ have been found in AD brains (Zheng et al., 2010). 
The Cu2+ levels in the serum of AD patients is 54% higher than controls (Squitti et al., 2002). 
The Cu2+ concentrations of 19.3 ± 6.3 µg/g are found in AD neuropil and up to 30.1 ± 11.0 µg/g 
in amyloid plaques (Lovell et al., 1998). Aβ has a high affinity for Cu2+ and coordination is found 





At physiological pH, Cu2+ binding modes are found with the distorted square planar geometry, 
which is preferred by the d9 metal ion. The slight fluctuation around physiological pH results in 
the structural interconversions between Figure 1.4A and B. The coordination mode of Figure 
1.4A is adopted at slightly lower pH, where Cu2+ binds via the histidine residues, N-terminal 
amine and carbonyl of the amide bond between Asp1-Ala2. At a higher pH, the binding mode of 
Figure 1.4B is found, in which the Cu2+ coordination through a histidine residue, N-terminal 
amine, the carbonyl of the amide bond between Ala2-Glu3 and the deprotonated nitrogen of the 
amide bond between Asp1-Ala2. As the interaction of Cu2+ and Aβ has been previously 
established, it will not be the main metal of focus in my study.  
 Zinc 
Zinc (Zn2+) is a d block metal with a d10 configuration and an atomic number of 30. It is one of 
the essential trace metal ions in living organisms - the second most abundant transition metal 
after iron (Fe2+/3+). In the recent decades, Zn2+ has been found to be involved in multitudes of 
biological functions. In the central nervous system (CNS), Zn2+ plays a central role in processes 
such as apoptosis, oxidative stress, immune defence, neurogenesis, motor coordination, memory, 
and synaptic plasticity (Lu et al., 2000; Smart et al., 2004; Kepp, 2012). The majority of Zn2+ is 
in the testes, muscle, liver, and brain (Chen et al., 2016). However, zinc dyshomeostasis has been 
associated with AD, and vascular-type dementia (Watt et al., 2011; Kawahara et al., 2014). 
Burnet (1981) was the first to suggest the role of zinc in AD pathogenesis. The genetic risk factor 
in familial AD, the ApoE4 gene is related to higher serum levels of Zn2+ (Mattson, 2004).  
Evidence indicates Zn2+ affect Aβ in numerous ways, via transcription factor zinc-fingers, as 
bound Zn2+ in active sites of proteases (Lovell, 2009), and direct coordination to Aβ40/42 (Yang 




(Bush et al., 1993). Consequently cleavage of APP is left to β and γ secretase which increases 
production of Aβ40/42 (Bush et al., 1994). Zinc-dependent amyloidosis is indicated to be a result 
from zinc-amyloid interaction (Mantyh et al., 1993). Under physiological condition in vitro, rapid 
Aβ aggregation mediated by Zn2+ have been observed (Huang et al., 2000 ).  
Similar to Cu2+, the interactions of Zn2+ and Aβ have been well documented (Yang et al., 2000; 
Danielsson et al., 2007; Faller and Hureau, 2009; Nair et al., 2010; Watt et al., 2011). Previous 
findings indicate that Zn2+ binds to Aβ in a 1:1 stoichiometry with a mononuclear binding site 
(Danielsson et al., 2007). The study found the majority of Zn2+ binding sites are located within 
the first 16 residues in the hydrophilic section of the N-terminal, as only two sites are present on 
the carboxyl terminal (Atrián-Blasco et al., 2017). The three histidine residues in the N-terminus 
of Aβ42 peptide, are involved in zinc binding (Danielsson et al., 2007; Watt et al., 2011) with an 
equilibrium between His13 and His14 for one binding position anticipated (Alies et al., 2016). 
Studies using Aβ analogues supported this equilibrium, finding that all three histidine residues 
(His 6, His 13 and His 14) are zinc binding sites (Liu et al., 1999; Yang et al., 2000).  
 
Figure 1.5 Proposed coordination mode of Zn2+ to Aβ. Structure is based on bibliographic 
data (Danielsson et al., 2007; Watt et al., 2011) with an binding affinity constant values (Ka) at 




Based on these studies the most plausible first-coordination sphere structure of Zn2+−Aβ is 
illustrate in Figure 1.5. The coordination mode of Zn2+ to Aβ, maintains the Zn2+ preferred 
tetrahedral geometry, binding through two histidine residues (His6 andHis13 or His14), as well 
as the N-terminus of Asp1 and the carboxylic acid R group of Glu11 (Gaggelli et al., 2007) Zn2+ 
along with Al3+ will be investigated in this study. 
 Aluminium 
Aluminium is the third most abundant metallic element found on earth (Exley, 2004). Due to its 
abundance Al3+ is readily found in water, airborne dust and foods. It is also used in antiperspirants 
sprays and medicines such as adjuvant in vaccines and antacids. The main contributor for the 
intake of Al3+ in humans is via food and drink. Al3+ is insidious as it accumulates over time. 
Since the kidneys are the key organ for detoxification, neurotoxic effects of Al3+ have been 
described in dialysis patients (Parkinson et al., 1981), who exhibited elevated aluminium 
concentrations in plasma and brain tissue. Such patients showed disorientation, memory 
impairments, and, at advanced stages, dementia (Parkinson et al., 1981). Al3+ exhibits a high 
affinity to proteins, which it is able to cross-link.  
Despite aluminium being defined as redox inactive, Al3+ can become redox-active with the use 
of a very harsh reducing agent (Myers et al., 2011). It also has potent pro-oxidant abilities 
demonstrated by the formation of an aluminium superoxide semi-reduced radical cation •AlO2
2+, 
which is more powerful oxidant than either O2
-• or HO2
-•(Exley, 2004). The ability of Al3+ to be 
a neurotoxin was established over 100 years ago (Yokel, 2012). Al3+plays a role in dialysis 
encephalopathy (Alfrey et al., 1976) and increases proinflammatory cytokines in the CNS 




increase the processes of metastasis (Darbre et al., 2013). Understandably the safety of Al3+ in 
humans has been controversial for a century. 
One of the major sources of Al3+ exposure is food preservatives or contamination from food, 
cooking and cookware, which accounts for an intake of about 20 mg/day (Greger and Sutherland, 
1997). Hence Al3+ is commonly absorbed through the gastrointestinal tract. The inhalation of 
Al3+ in antiperspirant aerosol or as air-borne particulates allows the absorption of Al3+ through 
across the respiratory tract into systemic circulation (Yokel, 2012). Aluminium adjuvants are 
also present in vaccines (Hem, 2002).  
Various Al3+ chemical species can occur in vivo, which possess various physical, chemical and 
biological properties. The presence of Al3+ have been detected in numerous biological fluids 
including urine (Davenward et al., 2013), CSF (Roos et al., 2013), sweat (Genuis et al., 2011) 
and seminal fluids (Hovatta et al., 1998). Aluminium is excreted from the body by a number of 
different modes of excretion, for non-systemic aluminium faeces is the major route and urine 
eliminates systemic aluminium (Ruipérez et al., 2012). 
According to UV spectroscopy and thermodynamic modelling two primary aluminium species 
exists in blood extracellular fluid (ECF) (Harris et al., 2003). In plasma, Al transferrin (Tf) 
accounts for approximately 93% and Al citrate accounts for about 5.5% of Al3+ species (Yokel, 
2012). Al3+ has no known biological role, however, it is present in human brain tissue in 
concentrations of 1.02 to 2.01 µg/g dry weight across the four main lobes (House et al., 2012). 
Al3+ has two potential routes to enter the brain from blood, firstly through the blood brain barrier 
(BBB) and secondly through the choroid plexus (CP) into the CSF (Xu et al., 1992; Allen et al., 
1995 ). Concentrations of aluminium is higher in plasma, but the metal ions can rapidly enter 




Al3+ is the first exogenous metal to be identified as a risk factor in AD, as reviewed by multiple 
authors (Neri and Hewitt, 1991; Bondy, 2010; Frisardi et al., 2010; Tomljenovic, 2011). Recent 
reports have indicated that the exposure to Al3+ contributes to the development of AD (Exley, 
2014). Studies found that in post mortem studies of familial AD patients the mean Al3+ 
concentration of the occipital, frontal, temporal and parietal lobes was 3.89, 3.66, 2.03 and 1.61 
µg/g dry weight respectively (Mirza et al., 2017). Oxidative stress is accelerated by Al3+ in vivo 
and in vitro (Khan et al., 2006). The reaction of Al3+ with superoxide (O2
-) produces radical ions 
(•AlO2
2+) which increase the Fenton and Haber-Weiss reactions (Exley, 2004). 
Unlike Cu2+ and Zn2+, Al3+ is not considered as an AD related metal and the metal ions 
association to AD is still controversial, because of insufficient evidence. However, numerous 
studies provide possible mechanisms for the involvement of Al3+ in amyloid plaque formation 
(Neri and Hewitt, 1991; House et al., 2004; Drago et al., 2008; Chen et al., 2011). Similar to 
other metal ions, Al3+ is found directly bond to Aβ in senile plaques (Yumoto et al., 2009). A 
study aimed to determine the different effects of Cu2+, Fe2+, Fe3+, Zn2+ and Al3+ on the 
aggregation and toxicity of Aβ showed that metal binding to Aβ significantly altered the chemical 
properties of Aβ, and that Al3+ was found to induce one of the most irregular aggregation 
behaviour, leading to the formation of highly toxic amyloid fibrils (Bolognin et al., 2011). 
Aggregation caused by the presence of aluminium was greater compared to zinc, copper and iron 
(Kuroda and Kawahara, 1994). Aβ bound to Al3+ was revealed to show the largest radius of 30 
nm for the resulting aggregates. Studies suggest trivalent metal ions such as Al3+ are significant 
to the formation of plaques, whereas Cu2+ and Zn2+ are deposited adventitiously (House et al., 
2004; Exley, 2006). Along with the effect of Al3+ on Aβ aggregation the use of enzyme-linked 
immunosorbent assay (ELISA) indicated Al3+ was the only metal ion bound Aβ species which 




demonstrated APP is upregulated in vivo, under Al3+ exposure in rat models. However, a 
contradicting study indicated that it did not increase the expression of APP compared to other 
AD related metal ions (Lin et al., 2008).  
The trivalent aluminium ion has an effective radius of 0.51 Å (Aghav et al., 2011). As it has a 
positive charge, the aluminium ion will readily accept electron pair donors and function as a 
Lewis acid. The high charge and small ionic radius of Al3+ gives it a strong polarizing effect on 
the adjacent atoms and can be classified as a hard Lewis acid (McCafferty, 2003). It can form 
complexes of higher stability with ligands containing hard donor groups. As a hard Lewis acid it 
has an affinity for bases. Ligands with the most effective donor atoms possess a strongly basic 
negative charge. In complexes Al3+ prefers binding to oxygen atoms due to the smaller size 
however, nitrogen binding also occurs (Djurdjevic et al., 2005). A coordination numbers of four, 
five and six are most commonly reported for Al3+, allowing the preferred geometry of tetrahedral 
and octahedral (Jennison et al., 1999; Streitz and Mintmire, 1999). Too many ligands 
coordinating to Al3+ would be less stable as a result of crowding a relatively small metal ion 
radius, however an insufficient amount of ligands would cause Al3+ into an unfavourable 
geometry (Urwin et al., 2016).  
The interaction of Al3+ and Aβ is the major theme of this thesis. Although the coordination of 
Al3+ to Aβ is implicated in the pathogenesis of AD, the molecular details of aluminium binding 
with Aβ is lacking until the present. This thesis will aim to determine the coordination of Al3+ in 
Aβ and determine the binding affinity, as well as study the effect of Al3+ on the expression of 




 Toxic metal exposure  
Since the early 20th century the industrial production and emissions of toxic metals have 
dramatically increased. This enhances the risk of exposure to human beings. Two highly toxic 
metal ions which are associated to our aging population are discussed below.  
 Arsenic 
Arsenic is naturally present in ground and drinking water, air and foods. Its mining and industrial 
usage leads to the increased contamination of water and crops. Rice, the staple food of Asia, often 
contains an elevated level of arsenic, due to pollution and its natural prevalence in ground waters 
originating from the river systems of the Himalayas (Sohn, 2014). The metalloid ion exists in 
multiple oxidation states, but mainly trivalent As3+ or pentavalent As5+. Both As3+ and As5+ are 
toxic. Particularly, As3+ is becoming increasingly abundant in our environment. This study uses 
sodium arsenite (NaAsO2), therefore, focusing on As
3+. In arsenic pathogenesis the reactive 
oxygen species-induced oxidative damage is a common characteristic, and arsenic also alters the 
integrity of mitochondria (Jomova et al., 2011). Chronic arsenic toxicity is a global 
environmental health problem affecting millions of people in the Unites States, Germany, 
Bangladesh and Taiwan. For example, an epidemiology study conducted by Lin et al (2013) 
evaluated the arsenic levels in drinking water and mortality of liver cancer in Taiwan, finding 
that within the analysed 20-year period, there were 1130 cases of liver cancer (802 males and 
301 females). The study found that villages exposed to arsenic concentrations of 0.64 mg/L and 
above from the water supply, showed an increase in the liver cancer cases. 
Furthermore, arsenic has also been linked to AD (Gong and O'Bryant, 2010). Arsenic toxicity 




precursor protein (APP), which are involved in the formation of neurofibrillary tangles and brain 
amyloid plaques (Dewji et al., 1995; Giasson et al., 2002). Compared to the research intensity on 
the other metals such as Cu2+, Zn2+ and Al3+, there is a limited amount of data about the effect of 
Ar3+ on neurons and Aβ aggregation. Anyhow, the association of Ar3+ with AD may have 
illustrated at least one aspect of AD, that is, there are many factors involved in AD development 
in humans. If the ligands used in this study could coordinate strongly to Ar3+, the therapeutic 
aspect of the ligand would be quite useful in ameliorating arsenic toxicity and its related health 
problems. 
 Chromium 
Chromium is the sixth most abundant element in the earth’s crust (De Flora, 2000). The benefits 
of chromium have been exploited in many areas such as leather tanning, electroplating, stainless 
steel production and clinical orthopaedics. It is predominantly found in the stable trivalent state 
or Cr3+ form, and the strong oxidizing hexavalent state (VI) or Cr6+ form (Barceloux, 1999). The 
hexavalent Cr6+ ion is highly toxic and has carcinogenesis effects in humans (Zhitkovich, 2011). 
The Birmingham hip resurfacing arthroplasty resulted in the significant increase in serum 
chromium levels (Weinstock, 1995). The body is able to reduce Cr6+ to Cr3+, which is imperative 
as Cr3+ is essential in the metabolism of cholesterol, fat and glucose, with required concentrations 
of 50 to 200 μg/day (Jones, 1990). However higher concentrations of Cr6+ can lower the body’s 
reduction capability, consequently the hexavalent ions will accumulate and damage DNA (Jones, 
1990; Nigam et al., 2014). Research has shown presence of Cr6+ increase the development of 
DNA adducts, DNA-protein cross links, breaking of DNA strands, the aberrations and instability 
of chromosomes (Hu et al., 2011). Nigam et al. (2014) found that a large group of genes had a 




critical to health, either excess amount or deficiency can adversely affect human’s health. So far, 
there is no evidence of chromium’s involvement in Aβ aggregation. However, if the ligands in 
my study prevent Cr6+ toxicity, the therapeutic aspect of the ligand would address various metal 
related health problems.  
In summary, mounting evidence demonstrates the role of metal ions in human metabolism and 
diseases. In recent years, a new view has emerged, which focuses on a more general picture of 
metal ion homeostasis (White et al., 2006; Singh et al., 2013). This view details interaction of 
metal ions with Aβ as just a part of the overall metal homeostasis process. This new thinking is 
in fact an extension of the metals hypothesis of AD, again accentuating the possible role of metals 
in Aβ aggregation and oxidation.  
 
 Alzheimer’s disease therapeutic rational 
The multifactorial nature of AD demonstrated by several pathological factors from, oxidation, 
inflammatory response, disruption of metal ion homeostasis, thought as the both the triggers and 
subsequent events of Aβ aggregation (Mantyh et al., 1993; Hou et al., 2004; Huang et al., 2004; 
Kurganov et al., 2004; Boyd‐Kimball et al., 2005; Hung et al., 2008; Bolognin et al., 2011; Meisl 
et al., 2016). This in turn supports the development of multifunctional therapeutic compounds in 
association to AD. Drug development for AD primarily focuses on Tau based and amyloid based 
strategies (Kepp, 2012). Considering the multiple factors are involved in the pathogenesis of AD, 
drugs targeting single causes are inefficient to prevent the progression of the neurodegeneration. 
The crucial role metal ions play in multiple pathways of AD supports that metal chelation therapy is 




following properties, restrict ROS production, metal chelating ability, high cellular uptake, ability to 
cross the BBB, antioxidant capabilities, reduce Aβ aggregation or inhibit Aβ production. However, 
designing metal chelators with selective and specific properties is highly challenging. As in the case 
of lipophilic metal chelator clioquinol (5-chloro-7-iodo-8-hydroxyquinoline, CQ), it significantly 
lowered amyloid plaques, resulting in improved cognitive behaviour in phase II clinical trials. 
However long term use of CQ, resulted in subacute myelo-optic neuropathy (SMON) (Cahoon, 
2009 ; Mancino et al., 2009). CQ did demonstrate a close association between metal 
dyshomeostasis and the onset and/or progression of AD, although the underlying biochemical 
mechanisms for some conditions remain unclear. Nevertheless, there is a beneficial aspect for 
BBB penetrable antioxidant and metal-chelating compounds (DeWeerdt, 2011). 
 
 Metal chelation therapy  
Chelation therapy is increasingly acknowledged as a worthwhile strategy for decreasing the 
abnormal accumulation of the metals such as copper, iron and zinc, as well as nonessential and 
toxic metals such as aluminium, cadmium, lead, mercury, chromium and arsenic (Yokel et al., 
1996; Andersen, 2004). Chelation therapy becomes an alternative treatment for AD albeit still 
controversial, in spite of the undesirable clinical results of the chelators such as CQ and EDTA 
(Bush and Masters, 2001; Treiber et al., 2004; Hegde et al., 2009).  
The underlying mechanism for metal chelation therapy is that coordination of chelating agent to 
a metal ion results in the formation of a stable complex, thus preventing the metal ion from 
interacting with other biological molecules such as Aβ. Developing an effective therapeutic 




the toxic metal, bioavailability, ability to penetrate cell membrane, high solubility, rapid 
elimination of metal ions, natural metabolism and excretion (Andersen, 2004).  
Many chelating compounds are found in natural products or well-known drugs for other purposes 
(Park, 2010; B Pocernich et al., 2011). This natural metal chelators approach could be adapted to 
AD therapies, due to the multifunction capabilities. As shown in Figure 1.6 a natural 
multifunctional metal chelator (MMC) could address all pathogenic factors of the amyloid 
cascade, metal ion and oxidative stress hypothesis previously illustrated in Figure 1.3. In addition 
to being antioxidant and metal-chelating, those compounds should also be capable of crossing 
the BBB and must be of reasonable small molecular weight. The panel of ligands I have used 
were selected for their known metal sequestering properties, namely, histidine, glutathione 
(GSH), maltol, citric acid and malic acid. These ligands are naturally occurring, easily 
metabolised and not toxic to humans. By screening of these potential ligands, desirable metal 






Figure 1.6 Proposed therapeutic intervention by multifunctional metal chelators on Aβ 
aggregation.  The multifunctional metal chelators (MMC) can lower the function of β-secretase 
by preventing metal ions from binding to APP at the α-secretase cleavage site, therefore 
allowing the formation of sAPPα, which is nontoxic. MMC can prevent the over-production of 
APP and hence reducing Aβ accumulation in the amyloid cascade hypothesis. Certain MMC 
have antioxidant capabilities which can reduce oxidative stress and scavenge ROS in the 
oxidative stress hypothesis. Excess metal ions, from the metal ion hypothesis, can be removed 
by MMC before their interactions with Aβ, preventing the formation of ROS and Aβ 




 Chelating ligands  
 Histidine 
Among the 20 naturally occurring amino acids, histidine (Figure 1.7) is the most active and 
versatile member that plays the multiple roles in protein interactions, often the key residue in 
enzyme catalytic reactions. This in turn accentuates the significance of histidine for Aβ which 
contains three histidine residues in its N-terminus. It is, in this regard, an almost perfect metal 
binding peptide. A vast body of literature demonstrates that the metal coordinating role of 
histidine is of no surprise (Van Campen and Gross, 1969; Djurdjevic et al., 2001; Arispe et al., 
2008; Shin and Saxena, 2008; Nair et al., 2010; Matsui et al., 2017). The imidazole side chain 
of histidine, shown in Figure 1.7, is a common coordinating site in metalloproteins and is a part 
of catalytic sites in many enzymes (Strange et al., 1987; Housecroft and Sharpe, 2008). The 
coordination role of histidine has also been applied in genetic engineering for protein expression 
and purification. Polyhistidine tag is widely used in design of gene constructs, so that the 
expressed proteins can be easily purified via nickel (Ni2+) affinity chromatography (Hochuli et 
al., 1988). 
 
Figure 1.7 Structure of histidine. 
Unlike the histidine residues in Aβ, as a free amino acid, histidine has four potential 




the imidazole. This study explores the role of histidine as a chelating ligand. Histidine may be 
able to form metal-ligand complexes with some of the metals of interest. This study will 
determine the binding affinity of histidine and metal ions, in comparison to the other ligands. 
The relative binding affinities of the ligands could determine the best coordinating ligands and 
can lead to future therapeutic agents. Smaller ligands like histidine have less steric hindrance, 
hence would readily bind to metal ions, prevent their accumulation and the subsequent 
aggregation of Aβ. 
 Glutathione  
GSH is a tripeptide (Figure 1.8) and is a prevalent endogenous antioxidant in the cell. GSH 
plays a fundamental role in detoxification of ROS and nucleophilic compounds, thus regulating 
the intracellular redox environment (Dringen, 2000). The concentration of GSH is decreased 
with age and in diseases with oxidative stress including AD (Liu and Choi, 2000). Neuronal 
cells are also protected against Aβ42 induced protein oxidation with the upregulation of GSH 
(Boyd‐Kimball et al., 2005), and GSH was found to provide protection against Aβ42 induced 
apoptosis in cortical neurons (Medina et al., 2002; Barber and Griffiths, 2003). Hence GSH has 
potential as a therapeutic strategy in AD treatment.  
In regards to the characteristic metal dyshomeostasis observed in AD, GSH is also one of the 
most versatile metal binding ligand, playing an essential role in metal storage, transport and 
metabolism (Hammond et al., 2001). The metal-related functions of GSH include the 
mobilization and delivery of metals to ligands, the cross transport of metal along cell 




GSH is a tripeptide made up of three amino acid residues, namely glutamate, cysteine and 
glycine. 
 
Figure 1.8 Structure of glutathione 
GSH is a multidentate ligand, with the presence of eight potential metal binding sites, though 
simultaneously coordinated to a single metal ion is not possible. Hence the coordination 
chemistry of GSH to metals allow the formation of polynuclear complexes (Krezel and Bal, 
1999). The eight donor atom of GSH are classed as the amine donors, carboxylate donors, the 
thiol group and the peptide bonds. Due to the variety of donor atom types it is of no surprise 
that GSH is a versatile metal binding ligand. GSH has a high affinity for metals forming 
thermodynamically stable complexes with numerous metals including Cr6+, Mn2+, Fe2+, Co2+, 
Au+, Ag+, Pb2+, Ni2+, Cu2+, Zn2+, Cd2+ and Hg2+ (Krężel and Bal, 1999; Wang et al., 2009; Liu 
et al., 2014; Ngamchuea et al., 2016). Hence this thesis will determine the molecular details of 
GSH in metal ion coordination, and its binding affinity with metal ions, in comparison to the 
other ligands. The comparison of GSH, an established metal chelator, to the other ligands could 
aid the determination of the strongest metal coordinating ligands. Multifunctional ligands such 





 Maltol  
The study of 3-hydroxy-2-methyl-4H-pyran-4-one or maltol (Figure 1.9) in this thesis stems 
from its ability to bind readily to metal ions. Maltol belongs to a family of hydroxypyrones, and 
it is a naturally occurring organic compound, often used primarily as a flavour enhancer 
(Liboiron et al., 2005). It is present in roasted malt (from which it gets its eponymous name). 
Humans have increased consumptions of malt foods. The maltol-metal complex, gallium 
maltolate, is an anticancer drug which is orally bioavailable (Bernstein et al., 2000; Chua et al., 
2006). Maltol is known to form extremely stable and neutrally charged complexes with a variety 
of metal ions, including the trivalent cations Fe3+, Al3+, Ga3+, and In3+ (Santos et al., 2005). 
Maltol has been found to increase the transport of Al3+ (Langui et al., 1990; Liboiron et al., 
2005). It can act as a strong bidentate ligand, coordinating through the carbonyl group and the 
α-OH group as seen in Figure 1.9. 
 
Figure 1.9 Structure of maltol 
Interestingly, the study conducted by Antipova et al. (2005) on the structure and stability of 
maltol–Al3+ complexes found maltol to be a suitable chelate ligand. With the AlMal3 complexes 
being electrically neutral, water soluble and relatively stable at the pH 4-8, the study concluded 
it fulfilled the requirements of a substance aimed to remove excess Al3+ ions within humans 
(Antipova et al., 2005). The potential of maltol being a therapeutic ligand is explored in this 




is a strong metal chelating ligand with little to no antioxidant ability. Hence the comparison of 
maltol to multifunctional ligands (GSH and histidine) would be worthwhile. 
 Citric acid 
Citric acid (2-hydroxy-1,2,3-propanetricarboxylic acid, Figure 1.10) plays a crucial role in the 
Krebs cycle, hence has a great biological significance and many roles in the human body, one 
of which is the ability of its conjugate base, citrate, to chelate metals (Silva et al., 2009). Due 
to this ability to form thermodynamically stable complexes with a variety of metal ions, it has 
found widespread use in food and pharmaceutical industries as well as in medicine 
(Wyrzykowski and Chmurzyński, 2010). The capability of citrate coordinating to Fe2+ has long 
been used by plants and microbes. For example, iron deficient Bradyrhizobium japonicum are 
known to secrete citric acid in order to enhance iron-absorption (Guerinot et al., 1990). The 
study carried out by Silva et al. (2009) on Fe3+ citrate speciation in aqueous solutions used 
spectrophotometric titration to determine the affinity constant for iron and citrate. The study 
found the following complexes were formed M2L2 - [Fe2(CA)2]
2-, M3L3 - [Fe3(CA)3]
3-, ML2 - 
[Fe (CA)3]
5-, MLH - [Fe (HCA)] (Silva et al., 2009), where M denotes metal, L denotes ligand.  
 
Figure 1.10 Structure of citric acid 
The study by Silva et al. (2009) describes citric acid as a multidentate ligand. The structure of 




donor sites capable of metal ion coordination such as an α-position hydroxyl group, one α-
position carboxyl group and two β-position carboxyl groups. Citric acid can assemble metal 
ions in diverse arrangements as both chelator and bridging spacer. Therefore, citric acid is a 
very appealing chelator, as monomeric, binuclear and polymeric metal complexes. Hence citric 
acid is explored for its metal chelating potential in this study.  
 Malic acid 
Malic acid (Figure 1.11) is a dicarboxylic acid. This organic acid is present in living organisms. 
It is non-toxic and used as a food additive. To reduce Al3+ toxicity, plants would release organic 
acids such as malic acid, citric acid and oxalic acid, from the root’s apex to stop Al3+ from 
entering the cell. The ability of malic acid to chelate metal ions has been previously investigated 
(Ma, 2000). The internal detoxification of Al3+ was accomplished by the formation of an Al3+-
malic acid complex (Ma, 2000). While malic acid cannot directly prevent the formation of 
reactive oxygen species, it is capable of detoxifying redox metals Cu2+ and Fe3+ (Salovaara et 
al., 2002; Brajenović and Tonković, 2003; Radalla, 2015).  
 
Figure 1.11 Structure of malic acid 
The five oxygen donor atoms of malic acid seen in Figure 1.11 allows the acid to act as a 
multidentate metal ligand. Despite the predominately acidic donor atoms of malic acid, it has 




Zn2+, Sm3+, Al3+, Ca2+, U6+ and In3+ (Markovits et al., 1972; Delhaize et al., 1993; Senthil Raja 
et al., 2013; Radalla, 2015). The metal chelating potential of malic acid is explored in this study. 
 
 Nuclear Magnetic Resonance (NMR) spectroscopy  
 Structural studies employing NMR spectroscopy 
Nuclear Magnetic Resonance (NMR) spectroscopy is used in the determination of structure and 
interactions between both Aβ peptide and ligands with metal ions at the molecular level. NMR 
is used to study the resonance frequency that results from the interaction of magnetic field with 
nuclei that posse magnetic dipole, such as 1H, 2H, 13C, 14C, 15N, 17O, 19F, and 31P. In the 
determination of protein/peptide’s secondary and tertiary structures, NMR spectroscopy is an 
important technique. The advantage of NMR compared to other techniques in structural biology 
and chemistry is its ability to analyse the samples in physiological conditions and is non-
destructive. This section will outline the general theory and principles of NMR spectroscopy. 
 General NMR theory  
NMR is based on the interactions between the magnetic moments of atomic nuclei and magnetic 
fields which can yield structural information. The subatomic particles such as electrons, protons 
and neutrons have four basic properties which include mass, charge, magnetism and spin. As 
measuring nuclear magnetism and spin have basically no effect on a substance’s physical and 
chemical behaviours, these properties can therefore be used to determine a compound’s 
structure without chemical composition disturbance. The nucleus has spin angular momentum, 
and may be considered as spinning about an axis, which is important in yielding NMR signals. 




magnitude 1/2, hence as a result the nucleus has a magnetic moment and generates its own 
magnetic field. Therefore, a sample that contains atomic nuclei with spin, has a magnetic field. 
When an external magnetic field (B0) is applied to the sample, the magnetic moments on the 
spins are either aligned with or against the magnetic field. Hence two spin states exist, the 
lower-energy, α spin state (+1/2) or higher-energy, β spin state (-1/2). The energy difference 
(ΔE) between the two spin states depends on the strength of B0.  
 
Figure 1.12 Energy levels for a nucleus with spin. In the presence of an applied magnetic 
field, the magnetic moments of the nuclei line up with or against the field.  
Net magnetisation (M) is produced by the alignment of the spins with the B0. During NMR 
experiments, short radio frequency (RF) pulses are applied, which excite all proton 
simultaneously and flip the direction of the nuclear spin alignment. This allows protons to 
absorb energy at a specific frequency known as Larmor frequency. Relaxation occurs when the 
atomic nuclei return to the original state, which generates induced magnetic signals. The RF 
signals recorded by receiver coils, are referred to as free induction decay (FID). The FID is 
mathematically processed by Fourier transformation which converts the signal into frequency 




the proton or 1H (hydrogen atom isotope), present in the molecules. As different protons in a 
peptide or molecule will have different chemical and magnetic environment, structural 
information from each proton can be extracted by NMR indirectly from the position of signals. 
Hence the ability to assign groups of resonances to a specific proton type within a protein. This 
includes the backbone 1H, side chain amide 1H, aromatic side chain 1H, aliphatic side chain 1H 
and αH in regions of β sheet structures (Reid et al., 1997). The NMR spectroscopy described 
thus far is known as one dimensional (1D) NMR spectroscopy. The technique is valuable in the 
analysis of small molecules. 1D NMR experiments can provide different kinds of information 
about a protein or peptide, which can be performed in physiological condition, allowing the 
structural configurations to be similar as those present in vivo. 
 Two-dimensional NMR spectroscopy 
Larger molecules such as peptides and proteins contain numerous magnetically non-equivalent 
nuclei, resulting in signal overlap. Hence the extension of 1D NMR into multiple dimensions 
is essential in the study of peptides. Two-dimension (2D) NMR spectroscopy plots the signal 
intensity of a 1D NMR along two frequency axes. Consequently, the peak in a 2D NMR spectra 
has an intensity and two frequency co-ordinates (Rubin, 2017). The homonuclear 2D NMR 
methods utilised in this thesis transfer magnetization between the same nuclei connected by 






 Correlated Spectroscopy (COSY)  
Correlated spectroscopy (COSY) yields signals from homonuclear through bond interactions 
(J-coupling). The bond connectivity of a molecule is determined through protons that are J-
coupled by two or three bonds (Arseniev et al., 1982). Simple COSY experiments, consists of 
90° pulses, involves an initial RF pulse (p1), an evolution time (t1), followed by the second RF 
pulse (p2), and then measurement time (t2). The initial RF pulse results in the magnetisation of 
the transverse plane which evolves over the time interval of t1. During the second RF pulse 
transfer magnetisation from one proton to the other proton. A COSY spectrum has two types of 
peaks, cross peaks and diagonal peaks. A COSY peak occurs at a frequency ω1 = ΩA, ω2 = 
ΩB which indicates the spin at the offset chemical shift (ΩA) is coupled to another spin at offset 
chemical shift (ΩB) (Keeler, 2005). COSY is a standard experiment for the analysis of scalar 
spin-spin through bond coupling connectivities. This method provides information for the 
identification of chemical shifts of spins that are coupled to one another, hence allowing 
determination of the J-coupling network in the molecule. 
 Total Correlation Spectroscopy (TOSCY) 
Total correlated spectroscopy (TOSCY) is another form of homonuclear 1H 2D-correlation 
NMR method, in which two 1H coupled spins indicate the existence of a cross-peak multiplet. 
TOCSY spectra provide correlations between all the protons of a coupled spin system or 
network. For TOCSY, the quintessential period is during the pulse sequence (mixing period) in 
which only scalar coupling is acting while the chemical shift is suppressed. During the mixing 
period, there is magnetisation exchange among J-coupling networks (Keeler, 2005). TOCSY is 
a useful method for the identification of coupled spins which belong to a network of spins, 




unambiguous spectra. These features are essential in the assignment of proton signals in a 
protein spectrum. TOCSY experiments are applicable to peptide studies as correlation cross 
peaks allows the identification of protons belonging to individual amino acid residues (Reid et 
al., 1997).  
 Nuclear Overhauser Effect Spectroscopy (NOESY) 
Nuclear Overhauser Effect SpectroscopY (NOESY) method identifies the spins undergoing 
cross relaxation and measures the cross relaxation rates. The NOESY results from direct dipolar 
couplings providing means of cross-relaxation, and only spins close to one another in space will 
undergo cross-relaxation (Wüthrich, 1986). In NOESY, experiments identify the Nuclear 
Overhauser Effects (NOEs) within a molecule, which enables the identification of protons 
within close proximity in space (Neuhaus and Williamson, 1989). NOESY experiments the 
pulse sequence involve three 90° RF pulses. The initial pulse results in the magnetization into 
the x-y plane which precesses in the evolution time t1. The following pulse rotates this 
magnetisation to the z axis which allows dipolar coupling with other spins during the 
subsequent mixing period. The third and final pulse forms a transverse magnetization from the 
remaining longitudinal magnetization. Following the third pulse, acquisition begins, and the 
transverse magnetization is expressed as a function of the time t2. NOESY spectra consist of 
cross peaks generated from the transverse magnetization. The non-equilibrium z component 
magnetisation is exchanged between the spin systems within close proximity via intra- or 
intermolecular dipolar relaxation during the mixing period (Wüthrich, 1986). NOESY is used 
in the sequential assignment of resonances and determination of the three dimensional structure 




 NMR assignments in peptides 
NMR provides essential structural data of peptide in solution. NMR assignments of the proton 
resonances are determined from 2D NMR experiments (Wüthrich, 1986). The signals from 
individual spin system are correlated to other spins through bond (J-coupling) or space (dipolar 
coupling) thus allowing the signal of every amino acid residue to be assigned. The identification 
of the amino acids in a sequence is performed by sequence-specific assignment method. Signals 
of individual spin systems are assigned through TOCSY experiments which provide through 
bond correlations of the resonances in same spin systems. Therefore, the cross-sections of the 
TOCSY spectra of Aβ peptide will illustrate cross-peaks from the NH to αH, βH, γH, δH, and 
aroH (if appropriate). The spin systems resonances are reference to published chemical shifts 
of random coil (Wüthrich, 1986; Reid et al., 1997). 
Identifying the position of the amino acids in the sequence is conducted by NOESY experiments 
which identify the protons of neighbouring amino acids that are close in proximity through 
space. Sequential distances are the distance between protons of two adjacent amino acids. In 
sequential NMR assignment, a spin system of amino acid residue starts with the proton of the 
backbone nitrogen (NH), followed by the proton on the α-carbon (αH) and then the side chain 
(βH, γH, δH, aroH, etc.). The typical chemical shifts proton in random coil peptides and proteins 









 Experimental approach 
This study utilises the analytical techniques of NMR spectroscopy in acquisition of molecular 
details of the interactions between metal ions and Aβ peptide. The use of NMR titrations 
provides information on the interaction of various ligands and metal ions, particularly the 
stoichiometric ratio, coordination sites and binding affinity. NMR titration of Aβ with metal 
ions reveals the residues involved in metal coordination. Whilst such titration reveals the effect 
of metal ions on the primary structure of Aβ, the effect of metal ions on the secondary structure 
of Aβ will be unravelled by the chemical shift index (CSI). KD values were obtained from 
chemical shifts variations (Δδ) in the titration of Al3+ and Zn2+. KD values determined which 
metal ion has the strongest binding affinity to the peptide. Furthermore, with the NMR titration 
of ligands with metal ions, their potential in metal chelation will be explored, which should aid 
future development of therapeutic agents for AD treatment. Molecular mechanics was used to 
determine the relative strength and stability of the metal ligand complexes. Following the NMR 
analysis for molecular details of metal coordination of Aβ and the metal chelation of ligands, a 
biological study was carried out using MTT cell viability assays on SH-SY5Y neuronal cells to 
establish the capacity of the ligands in reducing metal toxicity. The effect of the ligands was 
also tested against the toxic metal ions, As3+ and Cr6+, which are not related to AD. This would 
expand the therapeutic potential to toxic metal exposure. Finally, the effect of metal ions on the 
expression of APP gene in the human neuronal cells and the antagonistic effect of the chelation 
ligands against the metal ions was investigated by quantitative reverse transcription polymerase 





 Aims  
1. To characterise the interactions between metal ions and Aβ by NMR. 
2. To determine specific aluminium binding sites in Aβ1-28.  
3. To analyse the interactions between metal ions and a repertoire of ligands, with NMR 
analysis and molecular mechanics. 
4. To uncover if the chelating ligands can reduce metal toxicity in mammalian neuronal cells 
using MTT assay. 
5. To uncover the effect of metal ions on the expression of amyloid precursor protein (APP) 






2 MATERIALS AND METHODS 
 General materials, reagents and treatments  
The required general materials were purchased from Sigma Aldrich, Sydney, Australia. All the 
specific chemicals and solvents used were of analytical grade or higher, obtained from 
commercial suppliers. The MilliQTM system (Millipore, Australia) was the source of filtered 
and deionised water, which was used to prepare all stock solutions, media and buffers.  
 Metal solutions  
All metal stocks solutions and treatments were made using zinc(II) nitrate hexahydrate (reagent 
grade, 98%), copper(II) chloride dihydrate (ACS reagent, ≥99.0%), aluminium(III) chloride 
hexahydrate (ReagentPlus®, 99%), sodium (meta)arsenite (≥90%) or chromium(VI) oxide 
(ACS reagent, ≥98.0%).  
 Ligand solutions 
All ligand stock solutions and treatments were made using maltol (analytical standard), L-
glutathione (reduced, ≥98.0%), L-histidine (ReagentPlus®, ≥99%; TLC), citric acid anhydrous 
(ACS reagent, ≥99.5%), DL-malic acid (ReagentPlus®, ≥99%). 
 Phosphate buffer 
The 90% H2O:10% D2O 10 mM stock solution of the phosphate buffer was prepared by 
dissolving the monobasic NaH2PO4.H2O (0.0780 g) and the dibasic Na2HPO4.7H2O (0.5188 g) 
in 225 mL Milli Q water and 25 mL D2O. The pH of the buffer solution was adjusted to 7.45 ± 
0.01 by titrating with concentrated hydrochloric acid solution. The pH of the solutions was 




 Synthesis of pyridoxal amino methyl phosphonic acid (PYRAMPA)  
A solution of (2.46 mmoles) 500 mg of pyridoxal hydrochloride salt in methanol was added 
dropwise to a solution of (2.46 mmoles) 273 mg of aminomethylphosphonic acid (AMPA). The 
reaction mixture was basified with the addition of (6.90 mmoles) 385 mg solid KOH. The 
characteristic deep orange-yellow colour of the Schiff base was observed. Methanol was 
removed under vacuum. Leaving the microcrystalline material of the tripotassium salt of the 
Schiff base behind. The base was reduced in 25 mL of dry methanol and the addition of 2 
equivalents of solid (2.1 mmoles) 81 mg sodium borohydride. Reduced material was 
concentrated by pumping off most of the methanol under vacuum. The mixture was acidified 
with the addition of minimum amount of 6.0 M HCl. The white precipitate was recovered by 
gravity filtration. After 48 hr the filtrate was transferred from room temperature to -4 °C for a 
further 48 hr for the crystallization of PYRAMPA. Yields of 83% of the theoretical, 0.68 g of 
product, was obtained. Melting point 263 ± 2 °C. 
 Synthesis of metal-maltol complexes 
Synthesis of each metal complex involved dissolving 3.15 g (0.025 mol) of maltol and 2.5 g 
(0.01 mol) of Zn(NO3)2.6H2O; 3.78 g (0.03 mol) of maltol and 2.71 g (0.01 mol) of AlCl3.6H2O; 
3.15 g (0.025 mol) of maltol and 2.50 g (0.01 mol) of CuCl2.2H2O in 160 mL in Milli Q water. 
Mild heating was used to assist dissolution. Once the maltol was fully dissolved the pH was 
adjusted to pH 8.3. The solution was further heated to 65 °C with gentle stirring to produce 
precipitate. When the reaction mixture was cooled and filtered, washed several times with 





 Procedures for NMR acquisition and analysis 
NMR experiments were performed on either a Bruker Avance 400 MHz (9.4 T) NMR 
spectrometer equipped with a BBFO probe or the Bruker Avance III 600 MHz (14.1 T) NMR 
spectrometer equipped with a BBI probe. 1D and 2D NMR spectra were collected at 298 K. 
Water suppression was achieved using WATER-suppression by GrAdient-Tailored Excitation 
(WATERGATE) sequence, with “W5” binomial rf pulses.  
 1D NMR experiments 
All 1D 1H experiments were recorded with 128 scans, 4 dummy scans, a spectral width of 12 
ppm, and an acquisition time of 1.70 s. Prior to Fourier transformation, the measured FIDs were 
zero-filled and then multiplied with an exponential window function with a 0.3 Hz line 
broadening. 
 2D total correlation spectroscopy (TOCSY) experiments 
TOCSY experiment employed a DIPSI2 sequence for isotropic mixing, with a mixing time of 
75 ms. The spectra were collected with 256 x 1024 data points. The number of transients 
collected for each FID were 16, and the FIDs were zero-filled to 1024 points in F1 dimension 
and to 4096 data points in F2 dimension before Fourier transformation. 
 2D Nuclear Overhauser Effect Spectroscopy (NOESY) experiments 
The NOESY experiments were acquired with two different mixing times, 250 and 600 ms. Data 
were zero filled to 2048 points in both F1 and F2 without linear prediction and then Fourier 
transformed with a sine-bell-squared window function shifted between 90° and 45°. A 





 2D NMR titration of Aβ1-28 against metal ions 
Samples for the NOESY and TOCSY NMR experiments were prepared by dissolving the freeze 
dried peptide to give a concentration of approximately 1.0 mM. The peptide concentration was 
then confirmed using the extinction coefficient (Gill and Von Hippel, 1989) of 1280 
M−1 cm−1 (due to the single tyrosine residue). The pH of the samples was determined before 
and after. The pH was adjusted using aliquots of 10-100 mM NaOH or HCl. Then transferred 
to 5 mm Norell® NMR tube. The addition of 1.0 molar equivalent metal ions to the Aβ peptides 
was performed using 9 µL from a 50 mM stock solution of Al3+ and Zn2+. NOESY and TOCSY 
NMR experiments were conducted on the apo Aβ peptide sample followed by the 1.0 molar 





 Binding affinity 
A varied Hill Equation was used to determine binding affinity (KD). In this technique the 
changes in chemical shift (Δδ) of resonances, caused by the addition of metal ions are measured. 
Values of KD were derived from the relationship between metal concentration and the Δδ, 
expressed in a binding curve by fitting the data to the Hill Equation (2.1) below using Origin 





                                                      (2.1) 
 Where:  
𝑦 = change in chemical shift corresponding to metal concentration 
𝛥𝛿𝑚𝑎𝑥 = the point at which the peptide is saturated by metal ions 
[m] = metal concentration corresponding with the change in chemical shift  
KD = the binding affinity, computes using 𝑥 value at half 𝑉𝑚𝑎𝑥 value. 
𝑛 = The Hill coefficient (n = 1) 
 
 
 NMR titration of ligands against metal ions 
The addition of metal ions to the Aβ peptides was performed using aliquots of the concentrated 
stock solutions for Al3+ and Zn2+, as indicated in Table 2.3 so the resulting solutions had MI+/Aβ 
mole ratio varying from 0:1 to 3:1. Metal ion and ligand solutions were made in 90% H2O:10% 






For the cryogenic storage, the freezing medium used was made from DMEM/F12 Hams for 
SH-SY5Y cells, supplemented with 20% FBS and 10% dimethyl sulfoxide (DMSO, Sigma-
Aldrich). 
 Establishment of cell line  
Cell were seeded into 75 cm2 tissue culture flask (Greiner Bio-One, Germany) at 2.1 × 106 cells 
in 12 mL complete DMEM/F12 Hams and incubated at 37 °C, 5% CO2 (Thermo Scientific 
HERA 150). Cultures were examined under an inverted microscope (Olympus CKX41) daily 
to monitor the health and confluence. Once cultures reached a confluency of 80%, cells were 
passaged into three 75 cm2 flask, or from one 75 cm2 flask to three 25 cm2 flasks. To carry out 
passaging, cells were washed with 5 mL of phosphate-buffered saline (PBS) (137 mM NaCl, 
2.7 mM KCl, 10 mM Na2HPO4 and 2 mM KH2PO4 at pH 7.4). Then trypsinised with 1 mL 
trypsin (Life Technologies, Australia) and incubated at 37 °C with 5% CO2 for 2-5 min. Once 
detached, the cells are resuspended in complete DMEM/F12 Hams medium. The cell 
suspension was mixed by gentle pipetting to ensure cell suspensions were homogenous. Then 
using a hemocytometer (Hawksley BS. 748) cells were counted and aliquots of the cell 
suspensions were pipetted into new 75 cm2 flasks and brought to a final volume of 12 mL 
complete medium, with flasks containing 2.1 × 106 cells. The cells were then observed under 
microscope to ensure consistency cell density and health. The flasks were then returned to the 
incubator for growth. 
Cell cultures for experiments in microtitre plates were produced from the 75 cm2 flasks with 
80% confluency according to culture maintenance procedures stated above. Once cells had 




hemocytometer (Hawksley BS. 748) cells were counted. The microtitre plates were seeded with 
the suspended cells at 7000 cells per well and incubated at 37 °C with 5% CO2 for 36 hr. 
 Cryogenic storage 
Frozen stocks preparation was accomplished by culturing cells in the 75 cm2 flasks in complete 
medium until 80% confluency. The cells were then washed using 5 mL PBS, then trypsined 
and incubated at 37 °C with 5% CO2 for 3-5 min. After detachment of cells, 10 mL of complete 
DMEM/F12 Hams medium was added to the flask and the cells were suspended by multiple 
aspiration by pipette. Cell suspension was then transferred to 15 mL Falcon tubes (Sigma-
Aldrich, Australia) and centrifuged (Allegra X-15R) at 900 g for 5 min. The supernatant was 
aspirated to resuspend cells in 3 mL of freezing medium. Suspended cell solution was then 
pipetted 1 mL aliquots into cryovials (Greiner Bio-one, Germany). The cells were slowly 
brought to -196 °C by being placed in an insulated styrofoam container (Sigma-Aldrich, 
Australia) at -80 °C (Thermo Scientific -80C ULT) for 12 hr, after which the vials were 
transferred to liquid nitrogen storage at -196 °C. 
 
 Cell viability studies of SH-SH5Y cells under metal-ligand treatment 
 Determination of IC50 of metal ions  
To determine the metal treatment concentrations IC50 values were calculated for SH-SY5Y 
cells, in microtitre plates consisting of 7000 cells in 190 µL of complete media, in each well. 
Plates were incubated at 37 °C with 5% CO2 for 36 hr. Following incubation cells were treated 
with 10 μL stock solutions at 20× the respective metal salts that had been filter sterilised. The 






before optical density was measured using a spectrophotometer (Multiskan EX, Thermo 
Electron, USA) at 600 nm. 
 
 Quantification of APP Gene Expression 
 Harvesting and purification of RNA for quantitative qRT-PCR 
The SH-SY5Y cells were cultured in 75 cm2 flasks to 80% confluence at which point 1 mL 
TRIzol™ reagent (Thermofisher) was added directly into the flask. The solution was aspirated 
several times to homogenise the lysate, then transferred to 2 mL Eppendorf tubes. To ensure 
complete dissociation of the nucleoprotein complexes, the resulting lysate was allowed to stand 
for 5 mins at room temperature before the addition of 200 µL of chloroform, subsequently 
followed by another incubation at room temperature for a further 3 min. Samples were then 
centrifuged for 15 min, 12000 g, 4 °C to separate the solution into three distinct phases. The 
RNA containing upper organic phase was transferred, without touching the white layer in the 
middle, into a new tube by careful pipetting. The addition of 0.5 mL isopropanol resulted in the 
precipitation of the RNA. Following the 10 min incubation the sample was centrifuged for 10 
min at 12000 g at 4 °C. Consequently, total RNA precipitated forming a white gel-like pellet at 
the bottom of the Eppendorf tube. The supernatant was discarded and 1 mL of 75% ethanol was 
added. The sample was vortexed for 5 sec then centrifuged for 5 min, 7500 g, 4 °C. The 
supernatant was removed and the pellet allowed to air dry. The dried pellet was resuspended in 
30 μL RNase-free water by aspirating numerous times. The resulting RNA sample was stored 
at -80 °C. The purity and recovery were determined by NanoDrop based on the A260/A280 
ratio and the peak shapes at 260 and 280 nm. The RNA pellet was dissolved in 50 µL of DEPC 







Figure 2.1. Schematic explanation of the principle underlying TaqMan technology. A) At 
the start of qRT-PCR, double stranded DNA melts due to the increased temperature. B) 
Temperature is lowered to an annealing temperature to allow the primers and probe bind to their 
specific target sequences. C) Taq DNA polymerase catalyses the extension of a new strand with 
the use of unlabelled primers and the cDNA template strand. When the polymerase reaches the 
TaqMan probe the reporter is displaced away from the quencher, causing fluorescence. With 
each cycle more reporter molecules are released, resulting in the increased intensity of 
fluorescence, in proportion to the amount of amplicon synthesized. Therefore, each cycle 




The generated data was analysed using the 2-ΔΔCT method (Schmittgen & Livak, 2008) where 
the cycle threshold of the gene of interest in the control is normalised to the cycle threshold of 
the endogenous control in control conditions, giving ΔCTc. The cycle threshold of the gene of 
interest under the experimental conditions is normalised to the cycle threshold of the 
endogenous control under experimental conditions giving you a value for ΔCTe. Then ΔCTe is 
normalised to ΔCTc to give ΔΔCT. The expression fold change is given by raising 2 to negative 
ΔΔCT (exponent). 
 
 Software packages 
Icon 3.1 was used to process and analyse NMR data. Assignment of proton resonances was 
done using SPARKY with published assignments for Aβ as a guide. Origin 9 software was used 
for determination of binding affinity. MNOVA used to format and display 1D NMR data. 
Molecular mechanics was conducted using HyperChem 8.0 and Chem3D 15.1. Statistical 







3 THE NMR STRUCTURAL ANALYSIS OF AMYLOID β 
PEPTIDE AND ITS INTERACTION WITH METAL IONS 
 Introduction 
This chapter aims to define the interaction of metal ions with the Aβ1-28 peptide. As described 
in Chapter 1.9, the interactions of biometals Cu2+ and Zn2+ with Aβ have been studied in the 
past years. The Aβ fragments, ranging from 12- 42 residues in length can bind metal ions. 
Danielsson et al. (2007) and Syme et al. (2004) determined the coordination geometry of, Zn2+ 
and Cu2+. The metal binding of Aβ indicates that the dyshomeostasis of Fe2+/3+, Cu2+  and Zn2+  
could induce senile plaque accumulation (Lovell et al., 1998; Bolognin et al., 2011; Oshiro et 
al., 2011; Craddock et al., 2012; Singh et al., 2013). In contrast to these biometals which have 
biological functions in the brain, aluminium (Al3+) has no biological role, and is present in 
human brain tissue in concentrations of 1.02 to 2.01µg/g dry wt across the four main lobes 
(House et al., 2012).  
Aluminium association to AD has been previously documented (Crapper et al., 1973; Perl and 
Brody, 1980). The exposure to aluminium has been indicated to contribute to the development 
of AD (Exley and Vickers, 2014). Aggregation of Aβ caused by the presence of aluminium was 
greater compared to iron, copper and zinc (Kuroda and Kawahara, 1994). However, the details 
of interaction between aluminium and Aβ has not yet been established.  
This chapter will determine, by NMR analysis, the specific coordination geometry and the 
residues involved in the coordination of Al3+ to Aβ, and the structural variations of Aβ as a 




H14A and H6,13,14A) are used to determine whether all histidine residues play an equal role 
in coordinating to the metal ion.  
Chemical shift perturbation (CSP) in a ligand follows changes in its chemical shifts when an 
interacting metal ion is added. Measuring CSP makes quantitative use of the chemical shift 
changes to probe the geometry and strength of the interactions. CSP is an extremely reliable 
method to determine interaction sites, provided that the crystal structure or peptide sequence is 
kno1wn and the spectrum is assigned. It is proposed that the examination of CSP of Aβ when 
metal ions are added will determine the location of the binding site, the affinity of the metal 
ion, effect of aluminium on the secondary structure of Aβ, and potential structure of a Aβ-Al3+ 
complex. Chemical shift changes are sensitive to structural changes and can be accurately 
measured. Therefore, genuine binding interactions will produce CSP. The analysis involves 
NMR titrations, measuring the chemical shifts at each point following the peak’s movement, 
and measuring how each peak moves throughout the titration.  Resonances affected by the metal 
additions are the possible binding sites for Aβ. The comparison of Al3+ and Aβ titrations to the 
previously published Zn2+ and Aβ titrations will indicate if the binding sites for the two metal 
ions are different or not. The titration of Aβ with Zn2+ will also indicate similarities or 
differences in binding sites and modes of the metal-Aβ complexes. Once saturated by metal 
ions, the chemical shift perturbation as a function of Δδ vs [Al3+]/[Aβ
1-28
] can reveal the 
stoichiometric ratio of the Al3+-Aβ complex. Moreover, the shape of the titration curve can 
often be fitted to obtain a value for the dissociation constant (KD) of the metal-peptide complex, 
which is a measure of affinity of Al3+ to Aβ. Measuring CSP makes quantitative use of the 
chemical shift changes to probe the binding sites, geometry and interactions. This would in turn 




 Results  
 Structural analysis and determination of binding sites in the metal-Aβ1–28 
complex  
3.2.1.1 Proton NMR assignments for Aβ1-28 residues 
In order to delineate the key binding sites of Al3+ in Aβ1–28, the resonance assignments of all 
protons in apo Aβ1-28 peptide alone were performed firstly by examining the TOCSY and 
NOESY cross-peaks, see Appendix B. TOCSY provided total correlation of proton spin system 
in each amino acid residue. NOESY provided sequential NOE correlations between the protons 
of neighbouring spin systems. NOEs occur due to dipolar couplings resulting from interactions 
of spins via space. Table 3.1 shows the chemical shifts of all protons in Aβ1-28 peptide. From 
the known assignments of HN protons, it is straight forward to assign αH and other side chain 














The incremental additions of Al3+ caused the perturbation of numerous NMR resonances, by 
means of broadening or chemical shifts variations. 1D 1H NMR spectra show that Al3+ affected 
signals from all the three histidine residues (His6, 13 and 14) by exhibiting up field shifts of the 
2H (Figure 3.1A) and 4H (Figure 3.1B) resonances of the imidazole side chain.  
This observation suggests the involvement of the histidine residues as the metal binding sites. 
The αH and two diastereotopic βH protons of Asp1 at 2.64 and 2.77 ppm in Figure 3.1C are 
also perturbed with the addition of Al3+. Therefore, the coordination of Al3+ to Aβ1-28 may also 
involve the N-terminus. Based on the 1D proton NMR spectrum other residues were unaffected 
by the addition of Al3+. Hence the binding sites of Aβ for Al
3+ are limited to the His6, His13, 
His14 and Asp1.  
To confirm these binding sites in Aβ, 2D TOCSY of Aβ containing 1.0 mole equivalent of Al3+ 
was conducted (Figure 3.2, full spectra in Appendix C) in order to determine which residue-
specific spin systems were affected by the metal ion. The addition of Al3+ caused perturbation 









Figure 3.4 1H NMR titrated spectra of Aβ1–28 and analogues. The spectra of Aβ1-28 apo as 
well as its analogues respectively (0 mol eq Al3+) and 1.0 mol eq Al3+ are shown in the amide, 
aromatic and βH regions. All peptides are at 1.0 mM concentration in 10% H2O:90% D2O, pH 
7.4 at 298K. 
 
The comparison of the spectra (Figure 3.4) of apo Aβ1-28 (bottom) and the Al
3+
 additions, 
indicate that the metal ion causes a significant decrease of His and Asp1 signals, as compared 
to the rest of the spectrum. The effects of Al3+ addition on all four analogues also caused line 
broadening of His resonances but the observed effects are not the equivalent to the original Aβ1-
28 spectra. The addition of Al
3+ to H6A caused significant line broadening of the Asp1 βH 
resonances. The 4H signals from His13 and His14 residues were not affected by the Al3+. 
However, Al3+ caused the 2H of His13 and His14 to experience a downfield chemical shift with 




and His14 residues are still clearly visible, and despite a small shifting upfield, are not 
significantly broadened upon Al3+ addition. However, from Figure 3.4 the signals of His 2H 
and Asp1 βH protons experiences the largest CSP of H13A. The H14A spectra show broadening 
of the His signals but remain unshifted relative to their apo spectra. Slight changes where 
observed in the H6,13,14A peptide analogue for the βH region shown in Figure 3.5 (see 
Appendix C for full spectrum), line broadening was seen overall but resonance did not 
experience changes in chemical shift, apart from Asp1.  
 
Figure 3.5 2D 1H TOCSY spectrum of Aβ1–28 H6,13,14A with Al3+. The βH region of apo 
Aβ1–28 H6,13,14A (black) with 1.0 mol eq Al
3+(blue) is shown. The Aβ1–28 H6,13,14A peptide 
is at 1.0 mM concentration in 10% H2O:90% D2O, pH 7.4 at 298K. The slow exchange cross 
peaks observed for Asp1 βH are highlighted. 
 
TOCSY results also indicated the only residue in H6,13,14A affected by Al3+ addition was Asp1 
as seen in Figure 3.5. As the βH was more affected than the αH and with aluminium’s oxygen 




together, the results with Aβ1–28 analogues confirm that the aluminium binding site in Aβ is in 
the N-terminus and are consistent with the involvement of the three histidine residues in the 
coordination.  
 Determination of binding affinity of Al3+ to Aβ1-28 monitored by NMR 
spectroscopy 
The binding affinity experiments used the 1H NMR titration and a varied Hill Equation to 
determine binding affinity (KD). In this technique the CSP of the residues caused by the addition 
of metal ions are measured as a change in chemical shift (Δδ). Values of KD were derived from 
the relationship between metal concentration and the Δδ. The binding curves are constructed as 
outlined in section 2.6, by fitting the data to the Hill Equation (2.1) shown below and by using 





                                                      (2.1) 
This experiment used CSP of the Aβ1-28 residues effected by the aluminium titration. The 
binding curves obtained for the Aβ1-28 are given in Figure 3.6 and for each concentration the 
respective steady state equilibrium values were plotted and fitted to the Hill equation for a 1:1 






Figure 3.6 Binding curve of aluminium to Aβ1-28. The sum of the chemical shift changes (Δδ) 
for the Aβ resonances as a function of aluminium concentration. The curve represents the best 
fit of the quadratic equation that describes 1:1 complex formation. The KD of Aβ1-28 and Al
3+ 
was 0.35 ± 0.03 mM.  
 
The curve in Figure 3.6 corresponds a binding affinity of (KD) 0.35 ± 0.03 mM and Δδmax = 
0.13 ± 0.01 ppm. This was derived from the average binding affinities of replicated titrations 



















The similar changes in chemical shift observed for the resonances of 2H and 4H of His 6, 13 
and 14 in Figure 3.7 suggest aluminium and zinc binds to the same binding site of Aβ1–28. For 
zinc, the KD = 0.28 ± 0.03 mM, indicating Zn
2+ has only a slightly higher binding affinity 
compared to Al3+ (0.35 ± 0.03 mM) at physiological pH. These results indicate a very similar 
complexing ability of Zn2+ and Al3+. 
 Structure of Al3+-Aβ complex 
3.2.5.1 Chemical shift index (CSI) based secondary structure  
The CSP approach provide a means to study the effects of metal ions on the secondary structure 
of Aβ peptide, using the chemical shift index (CSI) based method developed by Wishart et al. 
(1992). The structural analysis based on the CSI method was conducted by comparing the 
chemical shifts of αH in an amino acid residue acquired from the NMR assignments to its 
random coil chemical shifts reference. This comparison assigns a chemical shift value in the 
form of a simple three-state (-1, 0, 1) index. A CSI value of ‘1’ is assigned to a residue if the 
measured chemical shift is greater than 0.1 ppm the CSI reference value; a ‘-1’ is given to 
residues with a αH smaller than the reference and a ‘0’ value is given if the experimental and 
reference chemical shifts are within the expected range. The use of these CSI values provides 
insights of secondary structure. An uninterrupted group of CSI values of three or more ‘-1’ 
indicates a helix. Any groupings of three or more ‘1’, uninterrupted by a ‘-1’, specify the 
presence of a β strand. All other regions are designated as random coils. The results of this 








Figure 3.8 The secondary structure of Aβ1-28 predictions from CSI values of αH chemical 
shifts. ‘+1’ and ‘-1’ mean the positive and negative deviation of chemical shifts from random 
coil values and refer to β strand and α helix structure, respectively. 
As indicated in Figure 3.8 the secondary structure of Aβ1-28 contains random coil near the N-
terminus and the possible α helix from Val18 to Asp23. The binding of metal ions would change 
the secondary structure of Aβ1-28 to allow the coordination geometry required of the metal, due 
to the rearrangement of binding sites donor atoms around the metal centre. Hence the effect of 
Al3+ on the CSI values and subsequent secondary structure of Aβ1-28 was measured and 
predicted. The secondary structural changes induced by Al3+ coordination can be seen in Table 
































































































































Figure 3.9 The secondary structure of Al3+-Aβ1-28 predicted from CSI values of Ha 
chemical shifts. ‘+1’ and ‘-1’ mean the positive and negative deviation of chemical shifts from 
random coil values and refer to β strand and α helix structure, respectively. 
 
The addition of Al3+ causes the secondary structure of Aβ1-28 to convert CSI values (Figure 3.9) 
from random coil and α helix to random coil and potential β strand from Glu11 to Gln15. The 
random coil supports the change of Aβ1-28 to coordinate to Al
3+ preferred geometrical 
arrangement. The β strand also demonstrates the effect of the constricted binding of both His13 
and His14 has on peptides backbone. Shortening the bond length is expected from the formation 


























































































































3.2.5.2 Stoichiometry of Al3+-Aβ complex 
A 1.0 mM Aβ1-28 peptide in 10% H2O:90% D2O was used in the titration to determine the 
stoichiometric ratio of the Al3+-Aβ complex, as shown in Figure 3.10. 
 
Figure 3.10 1H NMR titration of Aβ1–28 with Al3+. The titration was carried out in D2O at 298 
K and at a pH of 7.45 ± 0.01. Apo spectrum is for 2.4 mg of Aβ1–28 dissolved in 10% H2O:90% 
D2O; the spectra are for the Aβ solution with incremental additions of Al
3+ ranging from 0.0-
4.0 molar equivalence (mol eq).  
 
The chemical shift variations seen at 7.60-7.80 ppm and 6.80-6.95 ppm represent the respective 
protons of 2H and 4H, for the histidine residues (His6, His13 and His14). From Figure 3.10, 
the complex stoichiometry was observed in the mole ratio plot of Figure 3.11, by using the 





Figure 3.11 Molar ratio vs Δδ plot for the incremental addition of Al3+ to Aβ1 –28. The 
concentration of Aβ1–28 is kept constant at 1.0 mM. The concentration ratio for Al
3+ to Aβ1–28 
was varied from 0 to 4 molar equivalents. The stoichiometry Al3+ to Aβ1 –28 was found to be 
1:1 as indicated by the abrupt changes in the slope of the curve.  
 
The molar ratio plot in Figure 3.11, demonstrates the sum of the change in chemical shift (Δδ) 
of histidine protons, caused by the incremental addition of Al3+ plotted against the molar 
equivalence to Al3+ ([Al3+]/[Aβ
1-28
]), the stoichiometric ratio of the Al3+: Aβ
1-28
 complex was 
determined through mole ratio plot as shown in Figure 3.11. The abrupt changes in slope of the 
curve the stoichiometric ratio of the Al3+/Aβ




























3.2.5.3 Proposed coordination of Al3+ to Aβ1 –28 
The structural data collected thus far from the broadening and chemical shift variation of 1H 
and 2D NMR data reveal the specific residues involved in Al3+ binding. These amino acid 
residues are recapitulated in Figure 3.12.  
 
 
Figure 3.12 Schematic representation of the most affected residues in Aβ1-28 by Al3+ 
addition.  
 
At 298 K and pH 7.4, the residues mainly affected by Al3+ addition are the Asp1 and the three 
His. This is followed by Lys28, Gly25, Arg5, Phen19 and Tyr10. These results give rise to the 








Figure 3.13. The proposed structure of Aβ1–28 complexed with Al3+. The Al3+ ion is 
coordinated through the imidazole nitrogens of the three histidine residues, His6, His13, and 
His14, the N-terminal Asp1 and Gly25/Lys28.  
 
The binding involves the three histidines, the N-terminal Asp1 and Gly25/Lys28. The Arg5, 
Tyr10 and Phen19 were not significantly affected by Al3+ and thus its direct binding was ruled 
out. The Δδ of Arg5, Tyr10 and Phen19, are expected from residues in a turn to accommodate 
the Al3+ coordination of neighbouring resides. The Δδ of the βH of Lsy28 and Gly25 suggest 
the respective C-terminus and carbonyl are involved in binding. Due to the proximity of His13 
and His14 it is impracticable the coordination for both is simultaneous. Instead it is suggested 
the imidazole rings of the residues His13 and His14 are in equilibrium for one binding position. 





The amyloid β peptide is a major component of insoluble amyloid deposits in Alzheimer's 
disease, and the ability of Aβ to exist in different conformations is dependent on residues 1-28, 
Aβ1–28 (Huang et al 2004), which is used in this study. Al
3+ is likely to induce irregular 
aggregation behaviour of the Aβ peptide the main constituent of the senile plaques that is the 
hallmark of AD (Bolognin, 2011). In AD patients, Al3+ ions are found in the brain tissue (Mirza 
et al., 2017). It has been found that Al3+ can mediate the formation of amyloid plaques (Zhang 
et al., 2011). The previous data collected by using UV, Raman microscopy, CD spectroscopy 
and atomic force microscopy (AFM) techniques in vitro have provided quantitative and 
qualitative insights into the binding of metal ions (Zn2+, Cu2+) to Aβ via the histidine imidazole 
rings in isolated senile plaque cores of Alzheimer’s disease brain (Dong et al., 2003; Syme et 
al., 2004; Danielsson et al., 2007; Marino et al., 2010; Bousejra-El Garah et al., 2011).  
By using 1H NMR my findings demonstrate that Al3+ ions interact with the Aβ peptide. The 1H, 
NOESY and TOCSY NMR spectra of Aβ with the bound Al3+ illustrate several exchange 
phenomena, perturbations in the spectra (Figures 3.1 to 3.3). Using various Aβ analogues the 
involvement of histidine residues in Al3+ binding was verified (Figures 3.4 and 3.5).  
Resonances perturbed by metal coordination are characteristically from protons within close 
proximity to the chelating metal ion. Data from Aβ1–28, Aβ1–28 H6A, Aβ1–28 H13A, Aβ1–28 H14A 
and Aβ1–28 H6,13,14A analogues suggest that all three histidine residues and N-terminal amino 
group are involved in binding Al3+ ions. Addition of Al3+ to H13A and H6A resulted in the 
greatest difference in spectra relative to Aβ1 –28, supporting the observation by Liu et al. (2008) 




in the Aβ of rats, and Aβ does not exhibit amyloid accumulation in aged rats’ brains (Huang et 
al., 2004). This may indirectly highlight the critical role of His13 in human Aβ aggregation. 
The involvement of the N-terminus and histidine residues in Al3+ coordination to Aβ1–28 is 
supported by Al3+ 2D NMR analysis in which only significant chemical shift perturbations of 
these residues are revealed. Previously identified residues in relation to coordination of metal 
ions including Ser8, Tyr10 and Val12 (Narayan et al., 2013) has no significant observable 
chemical shift variations. In summary, residues perturbed by the presence of Al3+ are primarily 
residues Asp1, His6, His13 and His14 while other resonances are relatively unaffected.  
The comparison of Zn2+ and Al3+ coordination to Aβ demonstrates that both metal ions have 
similar potential to compete and strongly bind to the same His 6, 13 and 14 residues, as Zn2+ 
and Al3+ have a strong affinity for histidine imidazole rings.  
The pathogenesis of AD involves the structural transition of Aβ from the predominantly random 
coil structure of soluble Aβ to a conformation of β-sheet in proto-filaments and aggregation of 
Aβ (L.C. Serpell, 2000). CSI data from NOESY and TOCSY suggest that the apo Aβ1–28 
produced a typical CSI values of the random coil and possible α-helix conformation. However, 
in the presence of aluminium the characteristic grouping of ‘+1’ CSI values of titrated Aβ 
indicates conformational change of the peptide backbone from a random-coil structure to β-
sheet. A β-sheet structure appears from Glu11 to Gln15. These observations provide support to 
the notion that Al3+ facilitates the transformation of the Aβ peptides from the initial random 
coil structure to the β-sheet in AD patients. This is consistent with studies by Zhang et al (2011) 
which was based on monitoring the Thioflavin T fluorescence and CD conformation curves of 
aluminium titrated Aβ40. Hence, the findings in this chapter on the interaction of Al
3+ with Aβ 




drinking water, food sources and medicinal adjuvants, its uptake and potential interaction with 
Aβ presents an insidious risk for aging humans. 
 
 Conclusion 
The interactions between metal ions Zn2+ and Al3+ with Aβ were analysed using NMR 
spectroscopy. The molecular data obtained through NOESY and TOCSY demonstrate, for the 
first time, that Al3+ can coordinate to Aβ strongly via the Asp1 and the three histidine residues. 
Secondary bind sites of the C-terminus and carbonyl of Lys28 and Gly25 are also indicated. 
The presence of Al3+ also initiates the transformation of Aβ secondary structure from random 
coil to β sheet, which is characteristic of amyloid oligomerization. The findings provide further 




4 CHARACTERISATION, AND ASSESSMENT OF METAL 
COORDINATING ABILITY OF LIGANDS FOR 
DEVELOPING POTENTIAL THERAPEUTIC AGENTS 
 Introduction 
As described in Chapter 1.3, metal ions (Mn+) play a wide range of roles such as enzyme 
cofactors, signalling messengers and redox participants in many physiological and pathological 
functions (Riordan, 1977; Okafor et al., 2017; Nam et al., 2018). Although biometals are crucial 
in neurobiological processes, metal ion overload or the presence of toxic metals such as 
aluminium are insidious to human health. Metal toxicity generally occurs as a result of 
exposure, dyshomeostasis and chronic accumulation. Molecules that have been designed to 
sequester excess metals from the brain are being explored as therapeutic agents in many 
neurodegenerative disorders, such as AD, Parkinson’s disease (PD), Creutzfeldt-Jakob disease 
(CJD), and Amyotrophic Lateral Sclerosis (ALS) (Opazo et al., 2003; Sayre et al., 2005; 
Slivarichova et al., 2011; Sheykhansari et al., 2018; Portaro et al., 2019). Specifically 
investigated here are chelating molecules in order to identify lead molecules for the 
development of potential therapeutic agents.  
The interaction of Al3+ with the Aβ peptide, shown in Chapter 3, is relevant to the in vivo 
environment, which in turn may play an important role in the aetiology of AD (D'Haese and De 
Broe, 2001; Bolognin et al., 2011; Exley and Vickers, 2014; Mirza et al., 2017). Increased 
concentrations of Cu2+, Zn2+ and Al3+ are thought to be responsible for amyloid β (Aβ) plaque 
development, due to the presence of these metal ions in the Aβ plaque of post-mortem AD 




With multitudes of alternative drug developments currently underway, Aβ metal-based 
therapeutics remains a promising prospect for the treatment of AD. However, the extended use 
of strong chelators such as CQ and desferrioxamine affects biometals homoeostasis, inhibiting 
physiological processes of essential metal binding to biomolecules including metalloenzymes. 
Apart from their cytotoxicity, these chelators rarely coordinate more Al3+. Therefore, to prevent 
the adverse effects of synthetic chelators and find effective Al3+ chelators, natural occurring 
molecules with chelating abilities would be ideal. 
Furthermore, metal-induced redox processes such as Cu2+, induces result in the formation of 
ROS and subsequently oxidative stress is another feature of AD (Multhaup et al., 1996; Bush 
et al., 2003; Saporito-Magriñá et al., 2018). Although what initiates the biochemical mechanism 
for AD is still unclear, it is a logical step to prevent the interaction of excess metals with Aβ, 
and at the same time address the oxidative imbalance. Current therapeutic interventions are 
aimed at metal ions clearance in the brain, without targeting the oxidative stress. Antioxidant 
treatments have been studied alone as palliative options for the alleviation of AD symptoms 
(Prasad et al., 2000). Therefore, this study aims to evaluate natural ligands, their chelating 
potentials and antioxidant abilities.  
I have used a panel of potential ligands (Figure 4.1) in a search for natural metal chelators. 
These ligands are naturally occurring, easily metabolised and not toxic to humans, including, 
histidine, glutathione, maltol, citric acid and malic acid. The amino acid, histidine has four 
potential coordination sites, through the carboxylate group, the amide group, and the two 
nitrogens of the imidazole. As presented in Chapter 3 the His6, His13 and His14 residues are 





calculations were performed with the aid of the computer programs, HyperChem 8.0 and 
Chem3D 15.1. These programs were employed for determination of the optimised structures of 
metal-ligand complexes, minimum binding energies and HOMO energy values.  
 
 Results 
 NMR analysis for the coordination of metal ions by individual ligands  
 Histidine 
The details of metal ion binding to histidine revealed by 1H NMR are shown in Figure 4.2, 
including 1H NMR spectra of histidine only (apo His), and histidine plus 0.5 molar equivalent 
of metal ion Al3+, Cu2+ and Zn2+ respectively. The spectrum for apo histidine is labelled with 
the corresponding resonances 1H δ (ppm) to the structure of histidine (top). The respective 






Figure 4.2 1H NMR spectra of metal ions with histidine. Experimental conditions: 10% 
H2O:90% D2O at pH 7.4 ± 0.05 (adjusted with phosphate buffer, the final phosphate 
concentration is 10 mM), assay temperature 298K. The chemical structure of histidine is shown 
(top) with assigned protons labelled for the corresponding resonances. Spectra from bottom to 
top are apo His, His + Zn2+, His + Cu2+ and His + Al3+. In each of the metal ion titrations, the 
[Mn+]/[His] ratios are 0.5.  
 
The resonances at 6.95 and 7.95 ppm, corresponding to imidazole 4H and 2H, were relatively 
most deshielded with the addition of Al3+ and Zn2+, indicating strong coordination of histidine 
through imidazole. The relatively small extent of deshielding and line broadening of the αH and 
diastereotopic βH at δ 3.90 and 3.10 ppm suggests the amide and carboxyl groups may also be 





the addition of Ni2+, seen in Figure 4.3, indicates the involvement of the imidazole NH. The 
relatively small extent of deshielding of αH and diastereotopic βH suggests the amide and 
carboxyl groups may also be involved in the weak coordination. The overall line broadening 
indicates slow exchange, consistent with the formation of two complexes for the copper 
coordination, as seen in Figure 4.4. 
 
Figure 4.4 Two proposed structures of the copper-histidine complex. Coordination modes 
of histidine to Cu2+ are glycine-like (N-Cu-O) and histamine-like (N-Cu-N).  
 
The changes in chemical shift (Δδ) caused by the incremental additions of metal ions, in the 1H 
NMR titration of histidine were calculated. The largest deshielding caused by metal titration 
was observed for 2H of the imidazole group. Figure 4.5 presents the mole ratio plots for the 






Figure 4.5 Molar ratio vs Δδ plots for the metal ions to histidine. The concentration of 
histidine is kept constant at 10 mM and the respective metal ion concentration was varied from 
0.0 to 2.0 molar equivalents. Each slope represents the respective change in chemical shift (Δδ) 
for the resonances against the [Mn+]/[His] ratio. The stoichiometry of Al3+, Zn2+ and Cu2+ to 
histidine was found to be 1:2 as indicated by the abrupt changes in slope. 
From the changes in the slope at lower mole ratios followed by the abrupt plateau after the 
[Mn+]/[His] of 0.5 indicates the stoichiometry of 1:2 for histidine complexes with Al3+, Cu2+ 
and Zn2+. 
With the determination of binding sites and stoichiometric ratio, molecular modelling was used 
to obtain structural information on the coordination modes. Molecular mechanic studies provide 
the energy minimized conformation. While solvent effect is important in the complexes, 
computational model isolated molecule calculations of the metal-ligand complexes without 
solvent effect or the coordinated water molecules. The bare system studies allow the analysis 
of interactions between metal ions and the ligands. The MM2 and Huckel calculations were 
employed in the determination of the metal-ligand complexes optimized structures, relative 





 Glutathione (GSH) 
In order to determine the metal ion binding sites in GSH, the 1H resonance assignments of all 
protons in the tripeptide were first performed employing 2D cosy NMR correlations (Figure 
4.6). Assignments are summarised in Table 4.2.  
 
Figure 4.6. 2D 1H-1H COSY NMR spectrum of GSH. Experimental condition: 10 mM GSH 
in D2O at pH 7.4 ± 0.05 (adjusted with phosphate buffer, the final phosphate concentration is 
10 mM), assay temperature 298K. The labelled GSH structure (top) correspond to the 






Figure 4.7 1H NMR titration of metal ion with GSH. Experimental condition: 10% H2O:90% 
D2O at pH 7.4 ± 0.05 (adjusted with phosphate buffer, the final phosphate concentration is 10 
mM), assay temperature 298K. The chemical structure of GSH is shown (top) with assigned 
protons labelled for the corresponding resonances. From bottom to top, apo GSH, GSH + Zn2+, 
GSH + Cu2+ and GSH + Al3+. In each of these later solutions the [Mn+]/[GSH] ratios was 0.5. 
The intensity of the δ ppm of CH was significantly reduced due to the proximity to the 




The complexation with Al3+ resulted in the broadening of the resonance peaks in GSH. The 
presence of signals of the two NH protons of the glycine and cysteine indicated that they are 
not directly involved in the coordination to Al3+. The NH signals are shifted upfield, which 
suggests that the neighbouring groups may be involved in coordination with the metal. The 
disappearance of the broad NH of glutamate indicates direct coordination at this site. However, 
as aluminium prefers oxygen donors, the loss of the NH2 signal may also reveal a strong 
coordination to the glutamic acid carboxyl group. Hence the binding interactions with Al3+ are 
mainly via two negatively charged carboxylate groups of glycine and glutamate.  
The addition of Cu2+ results in the βH resonance of the cysteine’s slight downfield shift with a 
considerable line broadening. Because of the Cu2+ redox potential, the overall oxidation shown 
in reaction Equation (4.1) takes place which results in the formation of the oxidised form of 
GSH, GSSH. The spectral change and lack of line broadening seen in Figure 4.7 can be 
explained in terms of the formation of Cu+-GS- as indicated in reaction Equation (4.2). Since 
Cu+ is a diamagnetic metal ion, excessive line broadening is not observed. However, with the 
addition of excess Cu2+ the resonances experienced the line broadening effect of the NH of 
glycine and cysteine, due to the formation of the paramagnetic GSSG-Cu complex 
corresponding to Equation (4.3). The significant down field shift of the αH of the glutamate 
residue is consistent with the coordination of Cu2+ to the carboxylate and amide groups.  
2GSH +  Cu2+  ⇌  (GSSH) + Cu+  +  H+                                    (4.1) 
GSH + Cu+  ⇌ (Cu+ − GS−)  +  H+                                       (4.2) 
GSSH +  Cu2+  ⇌  (Cu2+ − GSSG) + H+                                   (4.3) 
The addition of Zn2+ resulted in the downfield shift of the NH of glycine and cysteine. This 




of glycine is also significantly deshielded suggesting the formation of the GSH-Zn2+ complexes, 
where Zn2+ is chelated by the NH2 or CO2
- of the end amino group of glycine. 
The numerical change in chemical shift (Δδ) caused by the incremental additions of metal ions, 
in the 1H NMR titration of GSH were calculated. The significantly large deshielding of each 
metal titration was observed for 1H resonances of the glutamic acid (E) αCH group. Figure 4.8 
presents the mole ratio plots for the [Mn+]/[GSH] and chemical deshielding for the Δδ of 
glutamic acid (E) αCH group. 
 
Figure 4.8 Molar ratio vs Δδ plots for the incremental addition of metal ions to GSH. The 
concentration of GSH is kept constant at 10 mM and the respective metal ion concentration was 
varied from 0.0 to 3.0 molar equivalents. Each slope represents the respective change in 
chemical shift (Δδ) for the resonances against the [Mn+]/[GSH] ratio.  As indicated by the slope, 
the stoichiometry of Al3+, Zn2+ and Cu2+ to GSH was found to be 1:2, with potential 1:1 binding 




From the abrupt change at lower mole ratio followed by the plateau in the slope after the 
[Mn+]/[GSH] of 0.5 indicates a stoichiometry of 1:2 for GSH complexes with Cu2+ and Zn2+. 
The mole ratio plot for Al3+ and Zn2+ with GSH indicates the possible formation of a 1:1 and 
1:2 complex for Al3+ and Zn2+. 
Due to the multiple binding sites detected for GSH, many configurations were tested. Using the 
data collected thus far, the electronic structure calculations were performed. Table 4.4 illustrates 
the GSH and metal complexes with the optimized structures, lowest relative binding energies 








  Citric acid 
The structure of citric acid has three ionisable protons; at pH 7.4 these acidic hydrogens would 
be deprotonated to from citrate as shown in Figure 4.10 (top). The symmetric configuration of 
citrate yields two enantiotropic CH2COOH groups, thus citric acid/citrate is classified as 
prochiral. The equivalent enantiotropic hydrogens of CH2 in citrate exhibit indistinguishable 
protons signals in NMR. As such the only proton detected by 1H NMR is the enantiotropic 
hydrogens at 2.51 ppm. The hydrogens resonances overlay each other but display splitting due 
to the prochirality of citrate. The 1H NMR metal titrations of citrate (CA) and metal ions (Al3+, 






Figure 4.10 1H NMR spectra for metal ions and citric acid. The chemical structure of citrate 
(CA) are indicated (top). Experimental condition: 10% H2O:90% D2O at pH 7.4 ± 0.05 
(adjusted with phosphate buffer, the final phosphate concentration is 10 mM), assay 
temperature 298 K. From bottom to top, apo CA, CA + Zn2+, CA + Cu2+ and CA + Al3+. In each 
of these later solutions the [Mn+]/[CA] ratios (from the bottom) is 0.5. The chemical structure 
of citrate (top) are indicated. The respective protons assignments of the doublet of doublets at 
δ 2.51 ppm is the enantiotropic hydrogens of the two CH2COO
- groups.  
Figure 4.10 shows the 1D proton NMR spectra of citric acid with 0.5 mole equivalent of metal 
ions, Al3+, Cu2+ and Zn2+. All resonances of citric acid are affected by the addition of metal ions 
with three ionisable protons. Citric acid is a tridentate ligand, with all three COO¯ groups acting 














The addition of Cu2+ and Zn2+ results in the upfield shift of the overlapping signal of the 
enantiotropic hydrogens, suggesting the coordination of the metal ions occurs via both terminal 
carboxylic acid groups. However, the addition of Al3+ caused significant splitting (Figure 4.11) 
as the two sets of CH2 protons are now visibly different. This observation is thought to be a 
result of Al3+ binding to one terminal carboxylic acid group, causing a loss in the molecule’s 
symmetry.  
 
Figure 4.11 1H NMR Al3+ titration of citric acid. 1st spectrum is for apo 10 mM citrate in 
10% H2O:90% D2O buffered by 10 mM phosphate at a pH of 7.4 ± 0.05 and at 298K; spectra 
2 to 7 are for incremental additions of Al3+ to the apo CA solution. In each of these later 
solutions the [Mn+]/[CA] ratios (from the bottom) are as follows: 2nd 0.10; 3rd, 0.20; 4th, 0.30; 
5th, 0.50; 6th, 0.75 and 7th, 1.00. 
The loss of symmetry caused by Al3+ coordination was demonstrated more clearly by the NMR 
titration in Figure 4.11 for the same solutions. The loss of symmetry of the enantiotropic 
hydrogens seen with the addition of Al3+ to citric acid indicates the coordination through the 
























The CSP of citric acid caused by the addition of Al3+ and Zn2+ were calculated and plotted in 
the mole ratio plots of Figure 4.12 to determine stoichiometry of the metal-citric acid complex.  
 
 
Figure 4.12 Molar ratio vs Δδ plots for metal ion and citric acid. The concentration of citric 
acid is kept constant at 10 mM and the respective metal ion concentration was varied from 0.0 
to 2.0 molar equivalents. Each slope represents the change in chemical shift (Δδ) for the 
resonances of the enantiotropic hydrogens against the [Mn+]/[CA] ratio. The stoichiometry 
(Mn+:CA) of the complex with Zn2+ was found to be 1:2 as indicated by the changes in slope. 
The mole ratio plot for the CA complex with Al3+ indicates multiple binding modes.  
The mole-ratio plot for the [Al3+]/[CA] indicated the potential stepwise formation of Al(CA), 
Al(CA)2 and Al(CA)3. This observation is consistent with the results obtained from molecular 
modelling (Table 4.7) data for this complex. The plateau of the mole ratio plot after the 0.5 







  Malic acid 
The details of metal ion (Mn+) binding to malic acid (MA) by 1H NMR are shown in Figure 
4.13, including 1H NMR spectra of malic acid only (apo MA), and malic acid plus 0.5 molar 
equivalent of metal ion Al3+, Cu2+ and Zn2+ respectively. At assay pH 7.4, the deprotonation of 
both carboxy groups of malic acid results in the formation of the conjugate base, malate. The 
spectrum for apo malate is labelled with the corresponding resonances and the structure of malic 






addition of Al3+, Cu2+ and Zn2+ implies that the involvement of malic acid’s hydroxyl group in 
metal binding  
The numerical change in chemical shifts (Δδ) caused by the incremental additions of metal ions, 
in the 1H NMR titration of malic acid were calculated. For each metal titration, the significantly 
deshielded 1H resonance within malic acid was that of CH group. Figure 4.14 presents the mole 
ratio plots for the [Mn+]/[MA] and Δδ of CH, to determine stoichiometry of the metal-malic 
acid complex. 
 
Figure 4.14 Molar ratio vs Δδ plots of metal ions to malic acid. The concentration of malic 
acid was kept constant at 10 mM and the respective metal ion concentration was varied from 
0.0 to 2.0 molar equivalents. Each slope represents the change in chemical shift for the 
resonances of the enantiotropic hydrogens against the [Mn+]/[MA] ratio. The stoichiometry 
(Mn+/MA) of the complex with Al3+ and Zn2+ was found to be 1:2 as indicated by the changes 







This chapter is about the ability of individual ligands to bind various metal ions. Naturally 
occurring metal chelators such as the ones I am reporting here may have therapeutic 
applications in the treatment and alleviation of age-related health problems like dementia. The 
panel of ligands in this chapter were selected for their metal-binding proclivity, lack of 
cytotoxicity, and potential antioxidant activity. 
1H NMR titration experiments show histidine binds strongly to Al3+, Zn2+ and Cu2+, at a 
biologically relevant pH 7.4, with a stoichiometry of Mn+: histidine of 1:2 (Figure 4.5). Histidine 
is the main metal binding site in Aβ (Chapter 3), hence its ability to coordinate as a free amino 
acid to Al3+, Zn2+ and Cu2+ is not unusual. The proposed binding schemes in Table 4.1 indicate 
the coordination to metal ions occurs via the N2-imdazole group, the NH and COOH groups. 
The energy minimization calculations performed by using molecular mechanics (MM2) 
demonstrated that the minimized energy structure for a bidentate ligand is lower than that of 
the tridentate. The observed upfield shift of the resonances 2H and 4H of the imidazole group 
supports the view that Al3+ binds to histidine relatively more efficiently compared to Zn2+ or 
Cu2+. This is further demonstrated by the significantly lower HOMO values for the Al3+-His 
complexes of -0.010 eV, judged by the computational molecular modelling studies. My results 
conclude that, histidine is a chelating ligand able to coordinate strongly with Al3+. The 
complexes formed with Al3+, Zn2+ and Cu2+ demonstrate the potential of histidine as a chelating 
ligand (with therapeutic value to AD). In addition, I have surveyed all 20 amino acids for their 
interaction with metal ions, see Appendix D. The findings shed light on the individual amino 




was a significantly strong metal chelator. This is further supported as indicated by Chapter 3 
findings that it is mainly the histidine residues in Aβ that confer its metal binding ability. 
The interactions between GSH and Al3+, Zn2+ or Cu2+ (Figure 4.7) show that each of these metal 
ions bind to the potential coordination sites of glutathione with a high degree of specificity, 
with the actual sites involved in metal binding being dependent on the type and concentration 
of the metal ions. At physiological pH, the coordination of the GSH to Al3+ occurred via the 
glycine and glutamate carboxylate groups. The mole ratio plot indicated the stepwise formation 
of a 1:1 and 1:2 Al-GSH complex consistent with the studies conducted by Wang et al. (2009). 
The energy minimization of the Al-GSH complex in 1:2 ratio yielded the configuration with 
the higher stability. GSH showed weaker coordination to Al3+, compared to Zn2+ thiol 
coordination. The titration of GSH with Cu2+ supports that the metal ion oxidised GSH in a 
two-step reaction resulting in the formation of the Cu+ and GSSH (Kato et al., 1999), when Cu2+ 
forms complex with GSH and catalyses the reaction (Singh et al., 2014). The rate of GSH 
oxidisation is decreased with the increased concentration of GSH, and this was found to be the 
result of the formation of an inactive Cu-GSH complex (Ngamchuea et al., 2016). GSH is a 
versatile endogenous antioxidant, which is abundant in the body. In this context it is significant 
that the GSH concentration is found to be significantly lower in hippocampal regions of AD 
patients (Mandal et al., 2015). The upregulation of endogenous antioxidants is vital in 
combating oxidative stress, a known characteristic of AD, thus helping to slow the disease 
advancement (Pocernich and Butterfield, 2012). As demonstrated here, GSH strongly 
coordinates to AD related metals. Such finding, in combination with its proven antioxidant 




The comparison of the steric energy of various conformations of the metal-maltol complexes 
gives information on the relative coordination strength and stability of those complexes. It was 
shown that the complexation of maltol with Cu2+ yielded the complex with the highest stability. 
Also, the HOMO values of Al(mal)3, -8.757 eV; Zn(mal)2, -8.900 eV; Cu(mal)2, -8.921 eV 
indicate great stability of these complexes. Maltol is known for high bioavailability, favourable 
toxicity profile and significantly high metal ion complex stability (Thompson et al., 2006). The 
synthetic modifications and extensions of maltol may increase the variety of its potential 
medicinal applications (Mukha et al., 2007).  
Interaction of the metal ions with the citric acid ligand in solution at physiological pH results 
in the formation of a metal-citrate complex in a 2:1 ratio for Cu2+ and 1:2 for Al3+ and Zn2+. 
The complexation of citric acid to Al3+ resulted in an asymmetrical complex, with the binding 
of one terminal carboxylic acid group to Al3+. With four available oxygen donors, citric acid is 
an ideal chelating ligand for Al3+, as indicated by the lower HOMO values of -10.742 eV for 
the Al(CA)3 complex compared to the -12.153 eV for Zn(CA)2 and -12.879 eV for Cu2CA 
complexes. The presence of Al3+ in Arabidopsis, Zn2+ in wheat, and Cu2+ in Zea mays cause 
the exudation of citrate from the root, which actively chelates the metal ions (Gramlich et al., 
2013; Dresler et al., 2014; Wang et al., 2018). While the ability to bind and chelate metals from 
biological systems is established, citric acid has relatively low affinity for metal ions, as evident 
from the comparison of HOMO values of the other ligands tested. This indicates while the 
chelating ligand may bind to Al3+, Zn2+ and Cu2+, citric acid may not efficiently eliminate the 
metal ions. Deng et al. (1998) demonstrated that by using rat models, citrate increases the 




A similar low affinity is seen in the complexation of malic acid to Al3+, Zn2+ and Cu2+. The 
relative energies of the metal-malate are indicative of the formation of the stable complexes. 
The HOMO values of -11.316 eV for Al3+MA, -11.520 eV for Zn2+MA and -12.618 eV for 
Cu2+MA, demonstrating a similar metal affinity as citric acid. 
 Conclusion 
In conclusion, the metal-binding properties for a panel of ligands were characterised by NMR 
and molecular mechanics. The relatively high affinity of maltol, GSH and histidine to Al3+, 
Zn2+ and Cu2+ suggests their potential in metal chelation, which should be explored in future 
for drug development against diseases such as AD. The diverse coordinating sites available in 
the ligands GSH and histidine demonstrate their effectiveness in chelating various metal ions. 
The fact that they are natural molecules in human cells is a convenient bonus, their usefulness 





5 THE IMPACT OF METALS AND LIGANDS ON THE GENE 
EXPRESSION OF APP IN NEURONAL CELLS 
 Introduction 
Thus far, there is a strong association amongst metal ions, Aβ and AD according to numerous 
publications (Cherny et al., 1999; Lynch et al., 2000; Adlard and Bush, 2006; Duce et al., 2011), 
the extent of which is still debateable (Pollard et al., 1995; Drew, 2017). My findings 
demonstrate a strong interaction of metal ions and Aβ (Chapter 3) supports the argument that 
both metal ions and Aβ play a role in AD. A complex neurodegenerative disease such as AD 
has no clear causative aetiology. However, in the past few decades most AD therapeutic studies 
were focused on targeting one factor at a time varying from preventing metal induced apoptosis 
to Aβ aggregation, metal-Aβ coordination, Aβ accumulation or oxidative stress. This chapter 
aims to explore the effect of metal ions on the expression of APP gene, and then to gauge the 
antagonistic action of ligands on metal ions which may up-regulate APP gene expression. 
Currently there is a deficiency of data on this front, nor is there any work carried out on 
chelating ligands which may intervene metal ions’ effect on APP gene expression. Therefore, 
it would be worthwhile to investigate the potential effect of metal ions on APP expression and 
to subsequently find a natural chelating ligand which can stop such metal ions in the process.    
I will now focus on the toxicity of Al3+, Cu2+and Zn2+, and additionally arsenic (As3+) and 
chromium (Cr6+) which might not relate to AD but are detrimental to human health (Kim et al., 
2011; Lambrou et al., 2012; Mahajan and Sidhu, 2019). To determine if metal ions, Al3+ and 




and then carried out qRT-PCR for analysing the expression of APP gene. In parallel, the effect 
of ligands on metal-induced APP expression (if any) was also analysed.  
 
 Results 
 Determination of IC50 of metal ions on SH-SY5Y cells 
Prior to investigating the effects of the metal ions on APP gene expression, their appropriate 
dosage was initially established. The experimental details of IC50 determination is described in 
Chapter 2.8.1, the dose response curves for each metal ion studied were acquired and the 
subsequent IC50 of each metal ion was determined. Figures 5.1 to 5.5 are the dose response 
curves for ZnSO4, CuSO4, Al(mal)3, CrO3 and NaAsO2, as well as solvent controls in human 
neuroblastomas cells (SH-SY5Y). The dose-response curves indicated the IC50 values for the 
metal ions was 180 µM for Zn2+ (Figure 5.1); 1000 µM for Cu2+ (Figure 5.2); 1000 µM for Al3+ 
(Figure 5.3); 18 µM for Cr6+ (Figure 5.4); 16 µM for As3+ (Figure 5.5). Consequently, the 










Figure 5.2 Dose-response curves of copper sulphate in SH-SY5Y cells. The cells were 
treated with a range of CuSO4 concentrations as indicated and the MTT assay was used to 
determine cell viability. The IC50 of Cu
2+ for SH-SY5Y cells was determined to be 1000 µM. 
Experiment consisted of eight replicates. The mean of triplicate experiments was used to obtain 































Figure 5.3 Dose-response curve of aluminium maltol in SH-SY5Y cells. The cells were 
treated with a range of Al(mal)3 concentrations as indicated and the MTT assay was used to 
determine cell viability. The IC50 of Al
3+ for SH-SY5Y cells was determined to be 1000 µM. 
Experiment consisted of eight replicates. The mean of triplicate experiments was used to obtain 






























Figure 5.4 Dose-response curves of chromium trioxide in SH-SY5Y cells. The cells were 
treated with a range of CrO3 concentrations as indicated and the MTT assay was used to 
determine cell viability. The IC50 of Cr
6+ for SH-SY5Y cells was determined to be 18 µM. 
Experiment consisted of eight replicates. The mean of triplicate experiments was used to obtain 































Figure 5.5 Dose-response curves of sodium arsenite in SH-SY5Y cells. The cells were 
treated with a range of NaAsO2 concentrations as indicated and the MTT assay was used to 
determine cell viability. The IC50 of As
3+ for SH-SY5Y cells was determined to be 16 µM. 
Experiment consisted of eight replicates. The mean of triplicate experiments was used to obtain 
each data point and SD values are represented as error bars. 
 
 The effect of metal chelating ligands on the cytotoxicity of metal ion in SH-
SY5Y cells 
To establish if the ligands can chelate the metals in physiological conditions and reduce metal 
toxicity, MTT assays were performed. Following the methods as described in Chapter 2.8.2, 
comparative cytotoxic response curves for each ligand plus each metal ion were obtained 
(Figures 5.7-5.11). For metal plus ligand, the treatment of the neuronal cells with each metal 





























Figures 5.7 to 5.11. Metal alone serves as the control for each metal ion treatment (Al(mal)3, 
CuSO4, ZnSO4, CrO3 and NaAsO2 respectively). 
 
Figure 5.6 Comparative cytotoxic response curves of copper treated with ligands. The SH-
SY5Y cells were exposed to increasing concentrations of CuSO₄ with each ligand including 
citric acid (2000 µM), malic acid (2000 µM), maltol (3000 µM), glutathione (2000 µM) or 
histidine (2000 µM), then incubated for 6 hr. The cell viability was determined by MTT assay. 
The values are the result of triplicate experiments and SD values are represented as error bars.  
The ligands protected SH-SY5Y cells against the cytotoxic effect of Cu2+ exposure (Figure 5.6). 
While the presence of GSH and histidine significantly increased cell viability against Cu2+, a 


































maltol and malic acid. The marked increase of cell viability by GSH and histidine against Cu2+ 
demonstrates the ligands’ ability to coordinate Cu2+ under the physiological condition for SH-
SY5Y cells.  
 
Figure 5.7 Comparative cytotoxic response curves of zinc treated with ligands. The SH-
SY5Y cells were exposed to increasing concentrations of ZnSO₄ with each ligand including 
citric acid (2000 µM), malic acid (2000 µM), maltol (3000 µM), glutathione (2000 µM) or 
histidine (2000 µM), then incubated for 6 hr. The cell viability was determined by MTT assay. 
The values are the result of triplicate experiments and SD values are represented as error bars.  
For zinc, GSH and histidine protected cells from the cytotoxic effects of zinc (Figure 5.7). Citric 
acid, malic acid and maltol are ineffective on the cytotoxic effect of zinc exposure, and 



































Figure 5.8 Comparative cytotoxic response curves of aluminium treated with ligands. The 
SH-SY5Y cells were exposed to increasing concentrations of Al3+ with each ligand including 
citric acid (2000 µM), malic acid (2000 µM), maltol (3000 µM), glutathione (2000 µM) or 
histidine (2000 µM), then incubated for 6 hr. The cell viability was determined by MTT assay. 
The values are the result of triplicate experiments and SD values are represented as error bars. 
For Al3+, the treatment of ligands protected SH-SY5Y cells against the Al3+ metal toxicity 
effect. As seen in Figure 5.8, GSH was the most effective in reducing metal toxicity and 
increasing the viability of the SH-SY5Y cells under physiological conditions. The marked 
increase of cell viability by GSH against Al3+, is followed by citric acid, histidine, malic acid 



































Figure 5.9 Comparative cytotoxic response curves chromium treated with ligands. The 
SH-SY5Y cells were exposed to increasing concentrations of CrO3 with each ligand including 
citric acid (2000 µM), malic acid (2000 µM), maltol (3000 µM), glutathione (2000 µM) or 
histidine (2000 µM), then incubated for 6 hr. The cell viability was determined by MTT assay. 
The values are the result of triplicate experiments and SD values are represented as error bars.  
The treatment of ligands significantly protected SH-SY5Y cells against the Cr6+ metal toxicity 
effect. As shown in Figure 5.9, GSH was the most effective in reducing metal toxicity and 
increasing the viability of the SH-SY5Y cells under physiological conditions. The marked 
increase of cell viability by GSH against Cr6+, is followed by histidine, maltol, citric acid and 



































Figure 5.10 Comparative cytotoxic response curves of arsenic treated with ligands. The 
SH-SY5Y cells were exposed to increasing concentrations of NaAsO2 with each ligand 
including citric acid (2000 µM), malic acid (2000 µM), maltol (3000 µM), glutathione (2000 
µM) or histidine (2000 µM), then incubated for 6 hr. The cell viability was determined by MTT 
assay. The values are the result of triplicate experiments and SD values are represented as error 
bars. 
For As3+, the addition of ligands drastically improved the cell viability under As3+ exposure 
(Figure 5.10). Histidine and GSH are comparatively the most effective in increasing the cell 
viability. Additionally, the treatment of maltol, citric acid and malic acid also resulted in a 
marked increase of cell viability. Thus, demonstrating the ligands’ ability to lower As3+ toxicity 


































 Gene expression of APP under metal ion exposure and the impact of 
chelating ligands 
Accumulation of Aβ is thought to induce neuronal death in AD (Cherny et al., 2001; Walton 
and Wang, 2009; Pham et al., 2010). The over-production of Aβ is facilitated by the 
upregulation of APP gene expression (Walton and Wang, 2009). Therefore, I investigated the 
effect of metal ions on the expression of APP gene. To detect the effect of Al3+ and Zn2+ on the 
mRNA expression of APP using qRT-PCR, I firstly treated SH-SY5Y cells with the IC50 of 
Al3+ and Zn2+ respectively, then prepared the total RNA from the treated and untreated cells, 
followed by qRT-PCR quantification. 
Relative expression of the APP gene was determined with reference to the expression of 
housekeeping gene GAPDH. A fold change of 1 indicates no change of the gene expression. 
Fold changes of >1 or <1 signifies the gene expression is increased or decreased, respectively.  
Figure 5.11 demonstrates that the exposure of SH-SY5Y cells to Al3+ or Zn2+ led to the increase 
in the expression of APP gene (p <0.01 for Al3+, p <0.05 for Zn2+) by 22.9% and 19.7% 
respectively. Clearly, the presence of either Al
3+ or Zn2+ resulted in significant upregulation of 







the treatment of chelating ligands (Figure 5.12), particularly histidine (p <0.01) and GSH (p 
<0.001). Under Al3+ exposure, the treatment of citric acid, malic acid (p < 0.05) and PYRAMPA 
(p < 0.05) down regulated the APP gene, to a lesser extent compared to histidine and GSH. The 
APP gene expression was reduced by 38.9% for histidine, 47.4% for GSH and 10.6% for citric 
acid against the respective controls. Compared to their controls, malic acid and PYRAMPA 
down regulated the gene expression of APP by 40.5% and 28.1%, respectively. However, the 
ligand treatment caused the upregulation of APP gene expression by 17.7% for malic acid and 
21.0% for PYRAMPA compared to the medium control. 
 
 Discussion 
 Ligands ameliorated the metal toxicity 
The titration with Al(mal)3, CuSO4, ZnSO4, CrO3 and NaAsO2 (Figures 5.1 - 5.5) demonstrated 
that these metal ions have distinct cellular cytotoxicity. However, the treatment of neuronal 
cells with chelating ligands protected against the deleterious effects of these metal ions (Figures 
5.7 - 5.11).  
The ligand, GSH, improved the cell viability by 60.1% for Al3+, 73.5% for Cu2+, 34.8% for 
Zn2+, 79.6% for Cr6+ and 57.8% for As3+, demonstrating its detoxifying ability. The molecular 
mechanisms preventing metal toxicity by GSH appear to follow two routes, namely its 
coordinating structure and its antioxidant activity. GSH is a proven antioxidant which can 
maintain the redox balance against biometals (Cu2+ and Zn2+) and toxic metal/metalloid (Cr6+, 




Magriñá et al., 2018), and the thiol group in GSH can act as a key metal binding ligand 
(Hernandez et al., 2015). The effectiveness of GSH in metal detoxification signifies its 
therapeutic potential for metal dyshomeostasis of biometals as well as over-exposure of 
nonessential and toxic metals. 
Likewise, the presence of histidine increased cell viability by 20.2% for Al3+, 54.9% for Cu2+, 
4.4% for Zn2+, 57.7% for Cr6+ and 70.1 % for As3+. The underlying molecular mechanisms by 
which histidine exerts this protective function against metal ions is likely due to its coordinating 
property and its antioxidant activity. Histidine was demonstrated as the most effective hydroxyl 
radical scavenger out of several investigated amino acids (Zs.-Nagy and Floyd, 1984) and it is 
well established to be able to bind to excess divalent metal ions (e.g. Cu2+ and Zn2+) (Van 
Campen and Gross, 1969; Sandstrom et al., 1985). Therapeutic use of histidine was explored 
by Matsui (2017), who found that the supplementation of histidine, at concentrations higher 
than 10 mM, can be effective in maintaining mitochondrial function by suppressing oxidative 
stress. Treatment of histidine increased both nitric oxide synthases (NOS) and total antioxidant 
capacity in neural tissue of rats (Milewski et al., 2015). 
Maltol improved cell viability by 15.3% for Al3+, 11.9% for Cu2+, 39.7% for Cr6+ and 42.7% 
for As3+. Intriguingly, it could not improve the cell viability under zinc treatment, rather 
exacerbating the cytotoxicity of Zn2+, with a decrease of 13.4% cell viability compared to zinc 
alone control. As a membrane-permeable chelator, maltol was found to facilitate the uptake of 
Zn2+ in erythrocytes (Brand and Kleineke, 1996), which explains the above finding in this study. 
Further evidence demonstrates that maltol increases the accumulation of Zn2+ in the cells in 
comparison to zinc in the form of zinc acetate, zinc chloride or zinc sulphate (Hider et al., 1990). 




facilitating the zinc uptake and in turn increasing zinc toxicity. With maltol exacerbating effect 
in Zn2+ toxicity as well as its lower improvement in cell viability for Al3+ and Cu2+, it is 
reasonable I believe to conclude that maltol might not be an ideal chelating agent for therapeutic 
purpose against Al3+, Cu2+ and Zn2+. However, the findings demonstrate that maltol is 
potentially useful against the toxic metal/metalloids, Cr6+ and As3+. Thompson (2006) 
investigated maltol as a therapeutic agent for toxic metalloids. Maltol as well as its close 
analogues hydroxypyrones and hydroxypyridinones have many medicinal applications, from 
the ability to remove or supplement metal ion absorption (Barrand et al., 1987), to forming 
complexes in contrast agents used in magnetic resonance imaging (MRI), and chemotherapeutic 
agents (Santos, 2002). Maltol and the analogues were demonstrated to have high affinity with 
a range of metal ions (Santos, 2002; Yu et al., 2002; Kaneko et al., 2004). 
Citric acid seemed to be effective in protecting cell against metal ion toxicity with an increase 
in cell viability of 39.5% for Al3+, 24.9% for Cu2+, 34.8% for Cr6+ and 38.8% for As3+. It is 
known that citric acid can stimulate plant growth, and enhance phytoextraction of metal ions 
(Brand and Kleineke, 1996), it is a better alternative environmentally to synthetic chelator 
EDTA (Ethylenediaminetetraacetic acid) in the removal of heavy metals (Chaturvedi et al., 
2015). It also acts as a superoxide anion scavenger (Van Den Berg et al., 2003) and in heavy 
metals contaminated sludge acts as a chemical extracting agent (Zhang et al., 2008). However, 
citric acid requires a low pH of 3 to be effective in extracting metal ions from the environment, 
which is not physiologically possible (del Dacera and Babel, 2006). In contrast, citric acid 
exacerbates Zn2+ toxicity by decreasing the cell viability (Figure 5.8). This might be explained 
by its ability to facilitate zinc uptake as citric acid is known to increase zinc absorption 
(Wegmuller et al., 2014). While citric acid was found to prevent Al3+ from binding to the serum 




et al., 2003). Also CD (circular dichroism) titration studies indicated citric acid could not 
reverse the β-pleated sheet conformation in Aβ aggregation caused by Al3+ (Samanta et al., 
2018). Therefore, considering my findings together with the previous literature, citric acid may 
not be an effective agent for AD patient in reducing metal overload. However, as citric acid is 
a harmless natural compound, it should be beneficial no matter how infinitesimal such benefit 
is. 
Malic acid increased the cell viability by 19.4% for Al3+, 24.9% for Cu2+, 34.8% for Cr6+, 38.8% 
for As3+ and decreased the cell viability by 40.5% for Zn2+. The increase in the toxicity of zinc 
by malic acid is due to the ability of malic acid to increase Zn2+ absorption (Saunders et al., 
2013). Malic acid can readily reduce Cr6+ to Cr3+ (Zhong and Yang, 2012) and the acid exhibits 
higher affinity for trivalent metals (Jones, 1998). This notion is also supported by the relative 
increase of cell viability in As3+ and Cr6+ treated cells I have found.  
 The effect of Al3+ and Zn2+on APP gene expression in SH-SY5Y cells 
APP gene encodes amyloid precursor protein (APP) (Ghasemi-Fasaei, 2012). The finding 
(Figure 5.11) demonstrates the relative expression of APP gene is upregulated in the presence 
of Al3+, which likely results in more amyloid precursor protein in neuronal cells. Walton and 
Wang (2009) also found similar results in animal models, which shows that Al3+ consistently 
derived from chronic oral ingestion resulted in upregulation of APP gene expression, and an 
increased APP deposition compared to the brains of the cognitively-intact controls. Therefore, 
the finding in this study adds further support to the role of Al3+ in the development of AD. 
Yet while aluminium is the main metal of interest in this study, its involvement in AD remains 




2012; House et al., 2012). In the brains of the cognitively-deteriorated rats, aluminium was 
accumulated in the cores of senile plaque of cortical neurons and astrocytes in the hippocampus 
(Walton and Wang, 2009). In vitro studies by Kawahara et al. (1994) found Al3+ readily 
promotes the aggregation of Aβ, which is supported by my findings in Chapter 3. Not only does 
Al3+ increase the relative expression of the APP gene, Zn2+ also elevates the expression of APP, 
albeit to a lesser degree than Al3+ (Figure 5.11). The increase of intracellular Zn
2+ by genetic or 
pharmacological methods in different cellular and in vivo systems consistently affect the 
production of Aβ and APP (House et al., 2004; Lovell, 2009; Bolognin et al., 2011). Although 
Zn2+ may play a role in multiple pathways relevant to AD. It is significate that APP production 
is regulated by Zn-containing transcription factors (NF-κβ and sp1) and Zn2+ is essential for 
their activity (Zabel et al., 1991; Zeng et al., 1991). In addition to the effect of Zn2+ on APP 
expression, Zn2+ also elevates processing of the protein. Normal non-amyloidogenic processing 
of APP by cleavage in the Golgi complex, leads to formation of sAPPα, a neurotrophic factor 
(Wilquet and De Strooper, 2004). Zn2+ inhibits the α-secretase mediated sAPPα formation 
pathway and increase generation of Aβ40 and Aβ42 (Bush et al., 1994). Altogether, these cellular 
and physiological observations strongly indicate that Al3+ and Zn2+ play important roles in APP 
production, Aβ aggregation and AD pathology. 
 Chelating ligand treatment decreases metal-induced APP gene expression. 
Finally, the effect of chelating ligands on metal-induced APP gene expression as I have reported 
was consequential, the ligands bring down the expression of the APP under Al3+ (Figure 5.12). 
GSH exhibited the greater decrease in relative expression of APP gene. This is in agreement 




expression. Yet another important aspect of the potential therapeutic value for AD in addition 
to its ability to reduce metal toxicity. 
Histidine treatment also lowers the expression of APP gene in Al3+ treated cells. Little is known 
about how histidine lowers APP gene expression. Based on the metal chelating and antioxidant 
ability of the amino acid previously discussed, it is likely it functions similarly to GSH. 
Histidine is yet another potential therapeutic ligand. 
In regards to the organic acids, citric acid and malic acid, they did down regulate APP in Al3+ 
treated cells, compared to the respective control. However, they alone, while not statistically 
significant, upregulated APP expression compared to the control. Similarly, PYRAMPA alone 
significantly increased the expression of APP, compared to the control. While citric acid, malic 
acid and PYRAMPA can chelate metals and down-regulate APP gene expression, this study 
indicates they are not as effective as GSH and histidine. With a complex neurodegenerative 
disease such as AD, multiple causative factors are involved. We need to develop therapeutic 
agents which can target multiple causative factors. Based on this study, GSH and histidine 
demonstrate multiple beneficial effects in metal toxicity and APP gene expression. They should 








The findings demonstrate that GSH and histidine significantly increased the cell viability in the 
presence of Cu2+, Zn2+, Al3+, Cr6+ and As3+. It is shown, for the first time, that Al3+ upregulates 
the expression of the APP gene in human neuronal cells, and that GSH and histidine can lower 
the gene expression of APP induced by Al3+ and Zn2+. My results provide more evidence for 
the involvement of metal ions such as Al3+ and Zn2+ in AD development, as they can upregulate 
APP gene expression in addition to their direct binding to the Aβ peptide. Furthermore, the 
findings demonstrate that the ligands GSH and histidine are effective in detoxifying metal ions 
and negate the metal-induced APP gene expression, clearly shows their strong potential in 








6 CONCLUDING DISCUSSION  
Alzheimer’s disease (AD) is a devastating neurodegenerative condition that poses major 
challenges to human health, with a prevalence of around 35 million patients worldwide (Atrián-
Blasco et al., 2017). In order to better understand the roles of metal ion in Aβ aggregation and 
in APP expression, I have focused on the molecular interaction of metal ions with Aβ peptide, 
the interaction of ligands with metal ions, and the effect of metal ions on the expression of APP 
gene which encodes amyloid precursor protein. The main discoveries presented in this PhD 
analysis are: 
1. the determination of the solution structure of synthetic Aβ1-28 complexed with Al3+ by 
NMR spectroscopy,  
2. the characterisation of the metal binding sites on Aβ1-28,  
3. the upregulation of the expression of APP gene by Al3+, and 
4. the presence of metal chelating ligands can lower the metal-induced APP gene 
expression, which should subsequently reduce the accumulation of Aβ.  
 
 Al3+ coordinates to Aβ triggering structural modifications and 
aggregation 
Exposure to Al3+ results in Aβ aggregation and neurofibrillary degeneration (Langui et al., 
1990; Bush, 2003; Exley, 2006) and increased Al3+ levels can lead to degenerating neurons in 
AD (Vasudevaraju et al., 2008; Exley and Vickers, 2014). Nevertheless, the role of Al3+ in AD 




to AD (Kawahara and Kato-Negishi, 2011). I have identified specific Al3+ binding sites within 
Aβ peptide, which provides further evidence for the association of Al3+ with AD.  
The binding of Al3+ to Aβ is manifested by the exchange phenomena which are evident in the 
1H NMR and 2D NMR data in Chapter 3. Comprehensive information for Aβ coordination to 
Al3+ was presented in Figure 3.13, and further verified by Aβ analogues. The amino acid 
residues involved in the Al3+ coordination was deduced from the TOCSY NMR. As indicated 
by Figure 3.3, the Aβ1-28 can coordinate to Al
3+ via the imidazole NH group of His6, His13, 
His14 and the N-terminal amino group or Asp1. As demonstrated by the titration of Al3+ with 
Aβ1-28, the CSP values of the αH Asp1 at 4.09ppm; His6 at 4.51ppm; His13 at 4.57ppm and 
His14 at 4.52 ppm were significant compared to other residues.  
The use of the Aβ analogue, H6,13,14A (where the His residues at positions 6, 13 and 14 are 
replaced by alanine residues) demonstrated that only Asp1 αH in H6,13,14A was significantly 
affected by Al3+ addition. Titration of H6,13,14A produced a slow exchange, indicating 
potential secondary binding sites of Al3+ within Aβ. Previous studies also suggest additional 
residues may interact specifically with Al3+ such as Gly9, Tyr10 and Glu11 (Narayan et al., 
2013). A computational simulation identified Glu3, Asp7, and Glu11 as likely site for Cu2+ and 
Zn2+ binding (Mujika et al., 2017). So, these negatively charged residues at physiological pH 
might also be able to bind Al3+.  
The stoichiometry of Al3+ to Aβ1–28 was 1:1, resulting in the proposed structural mode of Al
3+ 
coordination to Aβ1–28, I presented in Figure 3.13. I found that Al
3+ has a similar affinity to Aβ 
compared to Zn2+. It is extensively known that Zn2+ is involved in Aβ aggregation (Arispe et 
al., 1996; Danielsson et al., 2007; Bolognin et al., 2011; Craddock et al., 2012). Zinc was 




for Al3+ to Aβ1 –28 is very similar to the KD of Zn
2+- Aβ1 –28 of 0.28 ± 0.03 mM (Alies et al., 
2016). Dissociation constant value for Al3+ has been reported for the first time.  
By using Aβ1-28 and its analogues (Aβ1-28 H6A, Aβ1-28 H13A, Aβ1-28 H14A and Aβ1-28 
H6,13,14A), the molecular details for the interaction of Aβ1-28 and Al
3+ via histidine have been 
delineated for the first time. As shown in Figure 3.13, the Al3+ ion is coordinated through the 
imidazole nitrogens of the three histidines, His6, His13, and His14. The N-terminal Asp1 and 
Gly25/Lys28. His13 and His14 coordinate in equilibrium for one binding position, His13 may 
be the preferred ligand in comparison to His14. These findings also suggest that His13 and 
His14 compete for one binding site due to their steric encumbrance (Faller and Hureau, 2009; 
Atrián-Blasco et al., 2017). The preference for His13 is supported by the finding that the 
methylation of His13 lowers the affinity for metal ions and thus depletes aggregation (Tickler 
et al., 2005; Smith et al., 2006). Interestingly naked mole-rats (Heterocephalus glaber) show 
greater homology to the human sequence, compared to the rat models (Rattus norvegicus), with 
only the arginine substitution for His13 (Andreeva et al., 2017). This subtle one residue 
variation, resulted in the interspecies difference in Aβ aggregation propensity and neurotoxicity 
(Smith et al., 2015). His13 is involved in the early formation of N-terminal β-sheet, found in 
amyloid plaques (Duff et al., 1996). With similar Aβ concentrations as the triple-transgenic 
mouse model (3xTg-AD), the naked mole-rats indicate no extracellular amyloid plaque 
formation or AD-like symptoms (Edrey et al., 2013). Therefore understandably from the 
importance of His13, this residue has even been targeted in AD therapeutic agents (Diaz et al., 
2006).  
The metal ion coordination with Aβ affects the secondary structure of Aβ. As indicated by 




Aβ from a primarily random coil structure to a proto-filaments and β-sheet conformation which 
is the key structural feature in aggregated Aβ. Between Glu11 to Gln15 a β-sheet structure 
appears, supporting the notion that Al3+ facilitates this structural transition important for Aβ 
aggregation (Serpell, 2000). These findings together demonstrate that Al3+ is interacting with 
Aβ peptide and therefore is likely involved in AD pathogenesis. 
Moving on to the effect of metal ions on Aβ at the gene level, I have asked whether metal ions 
can increase the expression of the APP gene. An upregulation of APP gene would most likely 
mean an increase of Aβ production in neuronal cells. The findings in Figure 5.11 demonstrate 
that the relative expression of APP gene is upregulated in the presence of Al3+ and Zn2+, 
suggesting that these two metal ions likely induce higher level of amyloid precursor protein and 
consequently more Aβ. The upregulation of APP gene by metal ions is a novel finding for 
human neuronal cells, although similar result was found in animal models (Lin et al., 2008; 
Walton and Wang, 2009). Possible modulation of the production and metabolism of Aβ by 
means of Zn2+-containing α-secretase was speculated in a previous review (Kepp, 2012), but 
no concrete evidence was provided. The presence of Cu2+ was also found to increase both the 
dimerization of APP and the extracellular release of Aβ (Noda et al., 2013). The current finding 
that Al3+ and Zn2+ upregulate the expression of APP gene in SH-SY5Y neuronal cells provides, 
for the first time, the experimental evidence for their potential role in regulating APP gene 
expression. 
Taken together the findings of Chapter 3 and 5, as summarised above, demonstrate that metal 
ions are involved in the interaction with Aβ peptide and in the upregulation of APP gene, they 
therefore could play a role in Aβ accumulation and aggregation. My work thus supports the 




hypothesis suggests that aggregation of the Aβ peptide into soluble oligomers and senile 
plaques is the main driver of AD (Hardy and Higgins, 1992; Karran et al., 2011; Barage and 
Sonawane, 2015), while the metal ion hypothesis suggests that disruption of metal ion 
homeostasis promotes Aβ aggregation and onset of AD (Zatta et al., 2009; Tabner et al., 2011; 
Kepp, 2012). Here in this study, the collective findings demonstrate for the first time that metal 
ions are involved in both metal-Aβ interaction and upregulation of the APP gene expression 
which in turn may lead to higher Aβ production. These findings suggest that metal ions and Aβ 
are partners in crime for the pathogenesis of AD. 
Whether Al3+ cause Aβ aggregation remains the subject of intense debate. However, I have 
shown that specific binding sites exist for Al3+, and that Aβ undergoes primary and secondary 
structural changes in the presence of Al3+. Finally, I have demonstrated the gene expression of 
APP is upregulated in the presence of Al3+ as well as Zn2+. These findings support the very 
strong link between Al3+ and Aβ. 
 
 Metal chelating ligands antagonise the role of metal ions in APP gene 
expression 
The aetiology of AD is complex. The ability of Al3+ to bind to Aβ as described in Chapter 3, as 
well as the previously established binding of Cu2+, Zn2+ and Fe2+/3+ to Aβ (Syme et al., 2004; 
Danielsson et al., 2007; Bousejra-El Garah et al., 2011), points to the involvement of metal ions 
in AD pathogenesis. This study also shows the presence of metal ions can cause conformational 
changes in the Aβ, which supports the notion that metal ions are linked to AD. Therefore, 




future researches. With AD having complex and multi-causative factors, multiple approaches 
are likely the effective way forward in combating the disease. Therefore, I have investigated 
metal chelating ligands to see if they can antagonise metal ions in their cytotoxicity and in their 
role of upregulating APP gene expression. 
The chelating ligands, GSH, histidine, maltol, citric acid and malic acid, did protect against the 
deleterious effects of metal ions. Histidine and GSH drastically increased cell viability in the 
metal induced cytotoxicity. GSH improving the cell viability by 60.1% for Al3+, 73.5% for 
Cu2+, 34.8% for Zn2+, 79.6% for Cr6+ and 57.8% for As3+. Histidine increased cell viability by 
20.2% for Al3+, 54.9% for Cu2+, 4.4% for Zn2+, 57.7% for Cr6+ and 70.1% for As3+. The 
potential for histidine as a metal chelator to antagonise metal’s binding to Aβ is ironically an 
epitome of fighting fire with fire, since it is mainly the histidine residues in Aβ that confer its 
metal binding. The protective activity of histidine and GSH are likely due to their coordination 
structure and antioxidant functionality, which incidentally addresses two causative AD factors, 
i.e. metal ions and oxidative stress. Histidine can bind to metals in a cellular environment with 
significantly less steric hindrance compared to Aβ. Histidine can also reduce oxidative stress 
and scavenge hydroxyl radicals (Zs.-Nagy and Floyd, 1984; Milewski et al., 2015). The 
structure of GSH contains donating atoms in the form of two carbonyls, an amide and thiol 
group. The number and diversity of coordination sites within GSH allow it to act as an efficient 
metal binding ligand. The antioxidant ability of GSH is well known (Forman et al., 2009; 
Wegmuller et al., 2014; Hernandez et al., 2015; Saporito-Magriñá et al., 2018). Therefore, these 
ligands can be used to combat Aβ aggregation and reduce reactive oxygen species. Of the tested 
ligands, histidine and GSH were the only molecules that did not increase the toxicity of Zn2+ 
(Figure 5.7). This suggests both histidine and GSH would not assist the transport of Zn2+ into 




(Wegmuller et al., 2014) and malic acid (Saunders et al., 2013), which facilitate the metal 
uptake. The usefulness of histidine and GSH as the ideal metal ligands is further supported by 
their ability to reduce the expression of APP gene. Whilst the mechanism of histidine and GSH 
in reducing APP gene expression is not clear, the finding here demonstrates their potential for 
AD treatment. Future studies on this front is warranted.  
 
 The significance and prospective directions 
Up until the present, the role of Aβ and metal ion in AD pathogenesis has been controversial. 
The findings I have reported demonstrate that Al3+ upregulates the expression of APP gene and 
binds to Aβ peptide. It also promotes the structural transition of soluble Aβ from a primarily 
random coil structure to the β-sheet conformation, a key feature of the aggregated Aβ. The data 
provide meaningful evidence for likely involvement of Al3+ in Aβ aggregation and AD 
development. Further studies on this front should be continued, at both molecular and clinical 
levels. 
This thesis further characterised a panel of metal chelating ligands (GSH, histidine, maltol, 
citric acid and malic acid) which may be useful to combating AD and heavy metal toxicity. 
They mediate the drastic reduction of metal induced cytotoxicity. Specifically, GSH and 
histidine showed the highest protective ability. GSH and histidine also reduced the increase in 
APP gene expression caused by the presence of Al3+ and Zn2+. This discovery has significance 
in the development of AD therapeutics. The underlying molecular mechanism for the role GSH 




In conclusion, I have provided significant evidence for the interaction of metal ions with Aβ. 
The molecular details of Al3+ interaction with Aβ and its role in upregulating APP gene 
expression are novel. The findings related to the metal chelating ligands histidine and GSH are 
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Appendix B: 2D NMR spectra for proton assignment of Aβ1–28 peptide 
NOESY spectrum (600 MHz) of Aβ1–28 in 10 mM phosphate buffer in 10% H2O:90% D2O, pH 







TOCSY spectrum (600 MHz) of Aβ1–28 in 10 mM phosphate buffer in 10% H2O:90% D2O, pH 








Appendix C: 2D NMR spectra for NMR titration of Aβ1-28 against Al3+ 
NOESY NMR spectrum (600 MHz) of Al3+ titrated wild-type Aβ1-28. Wild-type Aβ1-28 in 10% 
H2O:90% D2O pH 7.4 at 298 K, apo (black) and one equimolar Al






TOCSY NMR spectrum (600 MHz) of Al3+ titrated wild-type Aβ1-28. Wild-type Aβ1-28 in 10% 
H2O:90% D2O pH 7.4 at 298 K, apo (black) and one equimolar Al







Appendix D: 1D NMR titration curve of α amino acid against Al3+ and Zn2+ 
The different colour spectra indicate the different binding ratios where blue at the light 
base of the spectra is the control run (no metal), red, 0.2; dark green, 0.4; pink, 0.6; 
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